CLINICAL TRIAL PROTOCOL

ADVANCE TRAUMA

Effects of Advanced Trauma Life Support® Training Compared to Standard Care on Adult Trauma Patient Outcomes: A Cluster Randomised Trial

Version 1.3.0, 2024-11-15

**Table of contents**

1. [Administrative information](#_bookmark0) 4
   1. [Changelog](#_bookmark1) 4
   2. [Study identifiers](#_bookmark2) 4
   3. [Contributors](#_bookmark3) 4
2. [Synopsis](#_bookmark4) 7
3. [Background and rationale](#_bookmark5) 8
   1. [Updated systematic review](#_bookmark6) 9
4. [Benefit-risk evaluation](#_bookmark8) 9
5. [Trial aim](#_bookmark9) 10
6. [Regulatory approvals and trial registration](#_bookmark10) 10
7. [Trial design and procedures](#_bookmark11) 10
   1. [Overall trial design](#_bookmark12) 10
   2. [Design justification](#_bookmark13) 11
   3. [Eligibility criteria](#_bookmark15) 12
   4. [Hospital selection](#_bookmark16) 12
      1. [Inclusions criteria](#_bookmark17) 12
      2. [Exclusion criteria](#_bookmark18) 12
      3. [Screening](#_bookmark21) 13
   5. [Cluster selection](#_bookmark22) 13
      1. [Inclusion criteria](#_bookmark23) 13
      2. [Screening](#_bookmark24) 13
   6. [Patient participants selection](#_bookmark25) 14
      1. [Inclusion criteria](#_bookmark26) 14
      2. [Exclusion criteria](#_bookmark27) 14
      3. [Screening](#_bookmark28) 14
      4. [Withdrawal criteria](#_bookmark29) 15
   7. [Procedures](#_bookmark30) 15
   8. [Biological sampling procedures](#_bookmark33) 16
   9. [End of trial](#_bookmark34) 16
   10. [Intervention and control treatment](#_bookmark35) 16
       1. [Description of investigational medicinal products](#_bookmark36) 17
       2. [Auxiliary medicinal products](#_bookmark37) 17
       3. [Concomitant use of other medications or treatments](#_bookmark38) 17
   11. [Randomisation](#_bookmark39) 17
   12. [Blinding](#_bookmark40) 18
   13. [Treatment after trial end](#_bookmark41) 18
   14. [Outcomes](#_bookmark42) 18
       1. [Primary outcome](#_bookmark43) 18
       2. [Secondary outcomes](#_bookmark44) 18
   15. [Handling of adverse and safety events](#_bookmark46) 19
       1. [Definitions](#_bookmark47) 19
       2. [Reporting and assessment of adverse and safety events](#_bookmark48) 20
       3. [Follow up of safety events](#_bookmark49) 21
   16. [Statistics](#_bookmark50) 21
       1. [General principles](#_bookmark51) 21
       2. [Analysis models](#_bookmark52) 21
       3. [Additional sensitivity analyses](#_bookmark54) 22
       4. [Estimation and reporting of within cluster correlations](#_bookmark55) 22
       5. [Sample size calculations](#_bookmark56) 23
       6. [Interim analysis](#_bookmark57) 23
   17. [Quality control and quality assurance](#_bookmark58) 23
   18. [Quality assurance and oversight](#_bookmark60) 25
   19. [Monitoring](#_bookmark61) 25
8. [Deviations, serious breaches and other reporting obligations](#_bookmark62) 26
9. [Audits and inspections](#_bookmark63) 26
10. [Ethics](#_bookmark64) 26
    1. [Compliance to the protocol, ICH-GCP and regulations](#_bookmark65) 26
    2. [Ethical review of the trial](#_bookmark66) 26
    3. [Procedure for obtaining consent](#_bookmark67) 27
    4. [Data protection](#_bookmark68) 27
11. [Insurances](#_bookmark69) 28
12. [Substantial changes to the trial](#_bookmark70) 28
13. [Collection, handling, and archiving of data](#_bookmark71) 28
    1. [Source data](#_bookmark72) 29
    2. [Variables](#_bookmark73) 29
       1. [Screening](#_bookmark74) 29
       2. [Consent](#_bookmark75) 30
       3. [Consent withdrawn](#_bookmark76) 32
       4. [Baseline](#_bookmark77) 32
       5. [Prehospital](#_bookmark78) 35
       6. [ATLS adherence](#_bookmark79) 36
       7. [Emergency department](#_bookmark80) 39
       8. [Hospital](#_bookmark81) 39
       9. [Surgery](#_bookmark82) 40
       10. [Imaging](#_bookmark83) 41
       11. [Transfusion](#_bookmark84) 41
       12. [Injury](#_bookmark85) 42
       13. [Individual mortality status](#_bookmark86) 42
       14. [Quality of life (EQ5D5L)](#_bookmark87) 42
       15. [Disability (WHODAS 2.0)](#_bookmark88) 43
       16. [Return to work](#_bookmark89) 48
       17. [Safety events](#_bookmark90) 49
       18. [End of study](#_bookmark91) 49
14. [Trial organisation](#_bookmark92) 50
    1. [Trial team](#_bookmark94) 50
    2. [Trial Management Group (TMG)](#_bookmark95) 51
    3. [Joint Trial Steering and Data Monitoring Committee (SDMC)](#_bookmark96) 51
15. [Funding](#_bookmark97) 52
16. [Special considerations](#_bookmark98) 52
    1. [Funding](#_bookmark99) 52
    2. [Potential amendments](#_bookmark100) 52
17. [Notification of trial completion, reporting, and publication](#_bookmark101) 52
18. [References](#_bookmark102) 53
19. [Appendices](#_bookmark103) 58
    1. [Initial hospital screening instrument](#_bookmark104) 58
    2. [In-depth hospital screening interview instrument](#_bookmark105) 63
    3. [Case Record Form](#_bookmark106) 70

# Administrative information

## Changelog

|  |  |  |
| --- | --- | --- |
| Version | Date | Details |
| 1.3.0 | 2024-11-15 | * Updated names of events in the table of procedures * Added new references * Added nested staircase design for measuring adherence, |

quality of life, disability and return to work

* Updated small sample correction to be based on best available evidence closer to the time of analysis
* Added contributors
* Removed reassessment of the sample size calculation from the interim analysis
* Revised details on measuring ATLS adherence
  + 1. 2024-08-26 • Added details on measuring ATLS adherence
       - Clarified the section describing the consent process
       - Fixed minor issues with how the variables were listed
       - Indicated non-routinely recorded data in the list of variables
       - Added Administrative information section with contributors
       - Added CTRI registration number

1.1.0 2024-05-09 Updated the primary outcome to in-hospital mortality and

spelling corrections. The primary outcome was updated following a voting procedure in the Trial Management Group.

## Study identifiers

* ClinicalTrials.gov identifier: [NCT06321419](https://clinicaltrials.gov/ct2/show/NCT06321419)
* Clinical Trials Registry - India identifier: CTRI/2024/07/071336

## Contributors

The following have contributed to the design and implementation of the trial:

Martin Gerdin Wärnberg [](https://orcid.org/0000-0001-6069-4794) Karolinska Institutet, Stockholm,

Sweden

Girish D Bakhshi [](https://orcid.org/0000-0001-9542-4428) Grant Govt. Medical College & Sir

J. J. Group of Hospitals, Mumbai, India

Debojit Basak [](https://orcid.org/90000-0002-8378-9689) Institute of Post Graduate Medical Education & Research and Seth Sukhlal Karnani Memorial Hospital, Kolkata, India

Abhinav Bassi [](https://orcid.org/0000-0003-0750-9179) The George Institute for Global Health, New Delhi, India

Johanna Berg [](https://orcid.org/0000-0001-7553-7337) Karolinska Institutet, Stockholm, Sweden

Shamita Chatterjee [](https://orcid.org/0000-0002-9460-108X) Institute of Post Graduate Medical

Education & Research and Seth Sukhlal Karnani Memorial Hospital, Kolkata, India

Kapil Dev Soni [](https://orcid.org/0000-0003-1214-4119) All India Institute of Medical Sciences, New Delhi, India

Karla Hemming [](https://orcid.org/0000-0002-2226-6550) University of Birmingham, Birmingham, UK

Vivekanand Jha [](https://orcid.org/0000-0002-8015-9470) The George Institute for Global Health, New Delhi, India

Jessica Kasza [](https://orcid.org/0000-0002-8940-0136) Monash University, Melbourne, Australia

Monty Khajanchi [](https://orcid.org/0000-0002-0898-6391) King Edward Memorial Hospital, Mumbai, India

James Martin [](https://orcid.org/0000-0002-6949-4200) University of Birmingham, Birmingham, UK

Anurag Mishra [](https://orcid.org/0000-0002-2302-0632) Maulana Azad Medical College, New Delhi, India

Samriddhi Ranjan [](https://orcid.org/0000-0002-4277-6662) The George Institute for Global Health, New Delhi, India

Principal Investigator, TMG chair and TT member

TMG member

TMG member

TMG and TT member

TMG member TMG member

TMG member TMG member TMG member

External statistician

TMG and TT member External

statistician

TMG member

TMG and TT member

Anna Olofsson [](https://orcid.org/0000-0002-9460-108X) Karolinska Institutet Trial Statistician, TMG member

Nobhojit Roy [](https://orcid.org/0000-0003-2022-7416) The George Institute for Global Health, New Delhi, India

Rajdeep Singh [](https://orcid.org/0000-0001-6593-2624) Maulana Azad Medical College, New Delhi, India

Lovisa Strömmer [](https://orcid.org/0000-0001-5424-7111) Karolinska Institutet, Stockholm, Sweden

Li Felländer-Tsai [](https://orcid.org/0000-0003-0693-6080) Karolinska Institutet, Stockholm, Sweden

TMG and TT member

TMG member TMG member TMG member

Abbreviations: TMG, Trial Management Group; TT, Trial Team.

# Synopsis

**Title** Effects of Advanced Trauma Life Support® Training Compared to Standard Care on Adult Trauma Patient Outcomes: A Cluster Randomised Trial

**Rationale** Trauma is a massive global health issue. Many training programmes have been developed to help physicians in the initial management of trauma patients. Among these programmes, Advanced Trauma Life Support® (ATLS®) is the most popular, hav- ing trained over one million physicians worldwide. Despite its widespread use, there are no controlled trials showing that ATLS® improves patient outcomes. Multiple systematic reviews emphasise the need for such trials.

**Aim** To compare the effects of ATLS® training with standard care on outcomes in adult trauma patients.

**Primary Outcome** In-hospital mortality within 30 days of arrival at the emergency department.

**Trial Design** Batched stepped-wedge cluster randomised trial in India.

**Trial Population** Adult trauma patients presenting to the emergency department of a participating hospital.

**Sample Size** 30 clusters and 4320 patients.

**Eligibility Criteria**

*Hospitals* are secondary or tertiary hospitals in India that admit or refer/transfer for admission at least 400 patients with trauma per year.

*Clusters* are one or more units of physicians providing initial trauma care in the emer- gency department of tertiary hospitals in India.

*Patients participants* are adult trauma patients who presents to the emergency depart- ment of participating hospitals and are admitted or transferred for admission.

**Intervention** The intervention will be ATLS® training, a proprietary 2.5 day course teaching a standardised approach to trauma patient care using the concepts of a primary and secondary survey. Physicians will be trained in an accredited ATLS® training facility in India.

**Ethical Considerations** We will use an opt-out consent approach for collection of rou- tinely recorded data. We will obtain informed consent for collection of non-routinely recorded data, such as quality of life and disability outcomes. Patients who are un- conscious or lack a legally authorized representative will be included under a waiver of informed consent. Note that consent here refers to consent to data collection.

**Trial Period** November 2024, to October 2029

# Background and rationale

Each year, 4.3 million people die from trauma1. Among people aged 10-24 and 25-49 years trauma is the largest cause of disability adjusted life years2. Most deaths from trauma occur within the first 24-48 hours3. Traumatic brain injury and exsanguination are the most common causes of trauma deaths4,5. Most preventable trauma deaths are caused by clinical judgement errors during initial resuscitation or early care including airway management and haemorrhage control, even though the deaths occur later during the hospital stay4,6.

Several trauma life support training programmes have been developed to improve the early management of patients in the hospital by providing a structured framework for as- sessment and treatment7–11. The proprietary Advanced Trauma Life Support® (ATLS®) is the most established trauma life support training programme and more than one mil- lion physicians in over 80 countries have been trained in the programme since the first course in 197812. In the US and many other countries training in ATLS® is virtually mandatory for trauma care physicians13. Uptake in low- and middle income countries (LMIC) has been slow, potentially due to high costs9.

There are three randomised studies showing that ATLS® improves knowledge and clinical skills14–16, but there are no randomised controlled trials or high-quality quasi- experimental trials indicating that ATLS® improves patient outcomes7,8,10,11,17. We conducted an updated systematic review (unpublished), and estimated a pooled risk ratio of 0.82 (95% CI 0.60; 1.11) from ten heterogeneous (I2 0.91) observational studies on the effect of ATLS on mortality (see Figure [1](#_bookmark7))18–27.

We conducted a pilot cluster randomised controlled trial (ClinicalTrials.gov NCT05417243) between April 2022 and February 2023 as part of our network grant to assess the feasibility of a full scale trial. We published the protocol for this pilot study28. Our pilot study enrolled 376 patients from seven hospitals across India (unpublished data) and shows that it is feasible to conduct the proposed trial with a high percentage of patients consenting to out of hospital follow up (78%), low loss to follow-up rate (1%), and low missingness in key variables (mean 0.8%).

To involve patients and the public in the planning of this trial we conducted 19 semi- structured interviews with trauma patients, caregivers, and community representatives (unpublished data). The aim of these interviews was to understand their views on the trial and important outcomes and the interviews showed high acceptability of our research and emphasised the importance of better recovery before discharge and func- tional outcomes at and after discharge, including pain, mobility and self-care activities. The interviews also highlighted return to work as an important outcome.

## Updated systematic review

We performed a systematic literature search in the Medline, Embase, Cochrane, Web of Science, CINAHL and Google Scholar databases (PROSPERO ID CRD42022373977). The last search was conducted on November 11, 2022. We developed the search strategy in Medline (Ovid) in collaboration with librarians at the Karolinska Institutet University Library. We limited the search to English language articles, searched all databases from inception, and screened a total of 7896 records. We used a random effects model to pool estimates across studies.




Figure 1: Summary of the updated system review. The forest plot shows the effect of ATLS on mortality. Abbreviations: RR, risk ratio; CI, confidence interval; ATLS, Advanced Trauma Life Support; I2, heterogeneity.

# Benefit-risk evaluation

The direct risks includes integrity violations and data leakage. We will mitigate these risks by employing rigorous data collection and storage mechanisms. The procedures that we will use to collect data will be direct observation of care, routine physical exam- inations, questionnaires, and extraction of already collected data from patient records, which are often seen as involving only minimal risk.

The long-term risks of the research and the risk that the research will be used in detri- mental ways are minimal. Our trial will assess the effect of Advanced Trauma Life Support® (ATLS®) on patient outcomes. Training in ATLS® is standard in many health

care systems and it is unlikely that training physicians in this programme induces any harm to participants.

We consider these risks weighed up by the potential direct benefit for the participants in the intervention phase, if ATLS® is found to improve patient outcomes, and by the potential for improved care for the trauma patient population.

# Trial aim

To compare the effects of ATLS® training with standard care on outcomes in adult trauma patients.

# Regulatory approvals and trial registration

We will submit this trial to the Health Ministry Screening Committee at the Indian Council for Medical Research for their approval. We will apply for ethical approvals from each participating hospital, The George Institute for Global Health in India and the Swedish Ethical Review Authority. We will register this trial with Clinical Trials Registry-India and ClinicalTrials.gov.

# Trial design and procedures

## Overall trial design

We will conduct a batched stepped-wedge cluster randomised controlled trial (see Fig- ure [2](#_bookmark14)). The stepped-wedge trial is a uni-directional cross-over trial but the time point when clusters cross-over from standard care to the intervention is randomised29. Each cluster will be at least one unit of physicians performing initial resuscitation of trauma patients in the emergency department of tertiary hospitals in India. The number of units that we will train in each hospital will depend on the sizes of these units and the volumes of patients that they see. If more than one unit is trained in the same hospital these units will be considered one unit for the purpose of randomisation. We choose this approach for two reasons: 1) it will not be logistically or financially feasible to train all physician in a given hospital; and 2) we need to balance cluster size with the number of clusters. We will conduct this trial in India because physicians providing initial trauma care in India are so far not routinely trained in ATLS® or similar programmes.

We will roll out the interventions to 30 clusters over six batches, so there will be five clusters in each batch. The clusters in each batch will be randomised to one of five im- plementation sequences, with one hospital randomised to each implementation sequence.

All clusters will transition through three phases, first a standard care phase, then a one month transition phase during which the training is delivered, and finally an interven- tion phase, for a total of 13 months. The implementation sequence determines how long the phases of standard care and intervention are. Patient participants will be followed up for a total of three months.

## Design justification

We use the cluster randomised design because the intervention cannot be randomised at the individual patient level. We use the stepped-wedge design for two reasons. First, this design is statistically more eﬀicient than the parallel cluster design when the number of clusters is limited30. In this trial, the number of clusters is limited because of the costs associated with ATLS® training and the available slots for ATLS® training in India. Second, the stepped-wedge design is likely to enhance participation and engagement because all clusters receive the intervention. The batched stepped-wedge design further improves feasibility as it does not require all clusters to start at the same time, and it is robust to potential delays in cluster recruitment31.




Figure 2: Trial design. Lines represent the duration of patient enrolment across clusters and phases. Clusters will be sequentially allocated to a batch based on when they enter the study. Within each batch clusters will then be randomised to an intervention implementation sequence.

## Eligibility criteria

Our trial include eligibility criteria on three levels: hospitals, clusters and patient par- ticipants. We include eligibility on both the hospital and cluster level to facilitate the screening process.

## Hospital selection

Hospitals will be secondary or tertiary hospitals providing trauma care in India. Hospital will be the unit of randomisation.

### Inclusions criteria

**Hospitals** must meet the following criteria:

* admit or refer/transfer for admission at least 400 patients with trauma per year or 35 patients with trauma per month for at least the last six months;
* provide surgical and orthopaedic emergency services around the clock; and
* have at most 25% of physicians providing initial trauma care trained in a formalised trauma life support training programme, like ATLS® or Primary Trauma Care (PTC).

### Exclusion criteria

**Hospitals** are excluded if they meet any of the following criteria:

* the hospital of the cluster implements a formalised trauma life support training programme [1](#_bookmark19) during the trial period; or
* the hospital of the cluster plan to implement or implements other major interven- tions[2](#_bookmark20) that affects trauma care during the trial period.

1These include but are not limited to the National Emergency Life Support (NELS) programme, the Basic Trauma Life Support (BTLS) programme, the Pre-Hospital Trauma Life Support (PHTLS) programme, the Trauma Nursing Core Course (TNCC) and the Advanced Trauma Care for Nurses (ATCN) programme.

2These include but are not limited to implementing of a trauma team approach, opening a trauma

centre and implementing a trauma quality improvement programme.

### Screening

The trial management group will compile a list of hospitals with potentially eligible clusters and reach out to them to assess their interest in participating in the trial. We will then screen hospitals for eligibility based on the criteria above, using a two-step procedure. First, we will approach hospitals to complete an initial hospital screening instrument (see Appendix Section [19.1](#_bookmark104)). We will then discuss each eligible hospital individually in the Trial Management Group before deciding whether to include it in the trial. We have this discussion because we strive to include hospitals that to a large extent conducts primary resuscitation of trauma patients, rather than hospitals that primarily receives transferred patients from other hospitals, but this is diﬀicult to formalise in the eligibility criteria. We will then perform a more in-depth interview with selected hospitals (See Appendix Section [19.2](#_bookmark105)). To avoid excluding centres we will also discuss plans to implement other potentially competing interventions during the trial period, and take these plans into account when assigning clusters to batches. For example, we are aware of the ongoing implementation of the National Emergency Life Support (NELS) programme in India, and will therefore not include hospitals that plan to implement this programme during the trial period. All screening steps and decisions will be logged using REDCap32,33.

## Cluster selection

Clusters are one or more units of physicians providing initial trauma care in the emer- gency department of secondary or tertiary hospitals in India. These units already exist in the hospitals and rotate through the emergency department on specific days of the week.

### Inclusion criteria

**Clusters** must meet the following criteria:

* admits or refers/transfers for admission at least 12 patients with trauma per month for at least the last six months; and
* no more than 25% of physicians providing initial trauma care trained in a for- malised trauma life support training programme.

### Screening

The screening of clusters is part of the hospital screening process.

## Patient participants selection

Patient participants are adult trauma patients who presents to the emergency depart- ment of participating hospitals and are admitted or transferred for admission.

### Inclusion criteria

**Patients participants** must meet the following criteria:

* age of at least 15 years;
* trauma occurred less than 48 hours before arrival at the hospital;
* present to the emergency department of participating hospitals, with a history of trauma defined as having any of the reasons listed in the International Classification of Diseases chapter XX as the reason for presenting;
* admitted, or died between arrival at the hospital and admission, or re- ferred/transferred from the emergency department of a participating hospital to another hospital for admission; and
* managed by a participating cluster in the emergency department.

### Exclusion criteria

**Patients participants** are excluded if they meet the following criteria:

* present with isolated limb injuries; or
* are directly admitted to a ward without being seen by a physician in the emergency department.

### Screening

Clinical research coordinators will screen patient participants either as they arrive to the emergency department or using emergency department registers. The patients or their representatives will receive written information about the study before they are discharged, including about their right to opt out at any time before final analysis. Phone numbers for out of hospital follow up will be extracted from the emergency department registers, and will be securely held only by the clinical research coordinators at each sites.

### Withdrawal criteria

Patient participants can choose to withdraw their consent for collection of non-routinely recorded data at any time before the final analysis. If they withdraw their consent for this data collection the clinical research coordinator will not collect any more of this data, which also means that no further follow-ups will be conducted. They can also choose to have the data already collected about them removed from the trial at any time before final analysis of the data. Withdrawal of consent or removal of data from the trial will not affect their care in any way. If the patient participant withdraws consent, follow-up of this participant will be performed according to the participating hospitals routine.

## Procedures

Table [3](#_bookmark31) shows an overview of trial procedures before and during patient admission, and Table [4](#_bookmark32) shows an overview of trial follow-up procedures. Clinical research coordinators will follow up patients daily until discharge to capture injury information. They will also follow up patients at 24 hours, 30 days and 90 days after arrival to the emergency department to capture mortality outcomes, and at 30 days and 90 days after arrival to the emergency department to capture functional outcomes and return to work. If patient participants are discharged before any of these follow-up time points, clinical research coordinators will follow up patients by phone.

Table 3: Overview of trial procedures before and during patient admission

Procedure Screening Consenting Initial assessment In-hospital care

Eligibility criteria √

Study information*1* √

Informed consent*1* √

Baseline data collection √

Prehospital data collection √

ATLS adherence*2* √

ED data collection*3* √

Hospital data collection √

Surgery data collection √

Imaging data collection √

Transfusion data collection √

Injury data collection √

Mortality data collection √

Assessment of safety events √

*1*Clinical research coordinators will inform patient participants about the study, including that they are free to withdraw their data from the study at any time, and approach them for informed consent for collection of non-routinely recorded data in person or telephonically.

*2*ATLS adherence will be assessed by observing the care provided to a random sample of patient participants.

*3*Emergency Department

Table 4: Overview of trial follow-up procedures

Procedure Within 7 days of discharge 30 days 90 days Mortality data collection*1* √ √ √

EQ-5D/WHODAS √ √ √

Return to work √ √

End of study √

*1*Will be ascertained daily from when the patient participant arrive to hospital until they leave the hospital, are discharged or die.

## Biological sampling procedures

This trial does not include biological sampling.

## End of trial

The trial ends when the last patient participant has completed the last follow-up. The trial may be prematurely terminated if it this is necessary for safety reasons affecting the risk-benefit balance or if the recruitment of subjects cannot be met within reasonable time limits. If the trial is prematurely terminated or suspended, the investigator should immediately inform the subjects about this and ensure appropriate treatment and follow- up. Decisions on premature termination are taken by the joint Trial Steering and Data Monitoring Committee and Trial Management Group.

## Intervention and control treatment

The intervention will be ATLS® training. The control will be standard care, meaning no formal trauma life support training. We will train the physicians that initially resuscitate and provide trauma care during the first hour after patient arrival at the emergency department. These physicians can be casualty medical oﬀicers, surgical residents, or emergency medicine residents, depending on the setup at each participating centre. The training will occur during the transition phase in each cluster. Our experience from our pilot study is that study sites adhere to the training slot alloted to them through the trial, so we judge the risk of clusters implementing ATLS® before their randomised implementation sequence as very low.

We will train the number units of physicians needed to reach the required patient sample size, but estimate that this will require training an average of ten physicians per hospital, which on average should be mean that we can train one to two units per hospital. This is possible because many hospitals in India organise physicians staﬀing their emergency departments in units, and the physicians in the same unit work together in the emergency

department on the same days of the week. We will therefore collect data only on the days when these units work. The units selected to constitute a cluster from each hospital will be a convenience sample out of all eligible units in those hospitals.

**Advanced Trauma Life Support® (ATLS®)12** is a proprietary 2.5 day course teach- ing a standardised approach to trauma patient care using the concepts of a primary and secondary survey. The programme was developed by the Committee of Trauma of the American College of Surgeons. The course includes intial treatment and resuscitation, triage and interfacility transfers. Leaning is based on practical scenario-driven skill sta- tions, lectures and includes a final performance proficiency evaluation. Physicians will be trained in an accredited ATLS® training facility in India. We will assess adherence to ATLS principles before and after implementing ATLS training.

**Standard care** varies across hospitals in India, but trauma patients are initially man- aged by casualty medical oﬀicers, surgical residents, or emergency medicine residents. They are mainly first- or second-year residents who resuscitate patients, perform inter- ventions and refer patients for imaging or other investigations. Compared with other settings where a trauma team approach is adopted, nurses and other healthcare profes- sionals are only involved to a limited extent during the initial management.

### Description of investigational medicinal products

This trial does not include any investigational medicinal products.

### Auxiliary medicinal products

This trial does not include any auxiliary medicinal products.

### Concomitant use of other medications or treatments

Other than implementing another formalised trauma life support training programme or other major interventions to change the care of trauma patients as specified in the exclusion criteria, concomitant use of other medications and treatments may be provided at the discretion of the investigators and will not be considered an exclusion criterion.

## Randomisation

We will assign clusters to batches as they are found to be eligible and receive ethical ap- proval. Batches will include clusters from hospitals in different regions to optimize trial

logistics. We will randomise the clusters alloted to each batch to the different interven- tion implementation sequences within that batch[3](#_bookmark45). We will balance the randomisation within each batch on cluster size, defined as monthly volume of eligible patient partic- ipants, using covariate constrained randomisation. The cluster sizes are expected to vary between 12 and 20 patients per month, based on our previous experiences. We will conceal the randomisation order for as long as it is logistically possible, considering that arrangements for sending physicians to ATLS® training need to be made in advance.

## Blinding

It is not possible to blind a stepped-wedge trial, because all clusters receive the inter- vention.

## Treatment after trial end

When the trial ends, the intervention will have been implemented in all clusters.

## Outcomes

### Primary outcome

The primary outcome will be in-hospital mortality within 30 days of arrival at the emergency department. Clinical research coordinators will extract information on death from patient hospital records. If the patient has been transferred to another hospital, the clinical research coordinators will collect data on this outcome by calling the patient or a patient representative, or by contacting the hospital to which the patient was transferred. Data on this outcome will be collected continuously during the trial.

### Secondary outcomes

* All cause mortality within 24 hours, 30 days and three months of arrival at the emergency department. Data on this outcome will be collected in the same way as for the primary outcome.
* Length of emergency department stay. Data on this outcome will be collected from patient hospital records.
* Length of hospital stay. Data on this outcome will be collected from patient hos- pital records.
* Intensive care unit admission. Data on this outcome will be collected from patient hospital records.

3Randomisation will be done using bespoke code from previous trials.

* Length of intensive care unit stay. Data on this outcome will be collected from patient hospital records.
* Adherence to ATLS® principles during initial patient resuscitation, up to one hour

after the physician has first seen the patient. This assessment will be done using a 14 item checklist covering the key steps of the ATLS® primary survey, which was modelled based on previous work on ATLS® adherence34. We will consider completion of all 14 steps as 100% adherence. The clinical research coordinators collecting the data will be trained by the trial team to do this, prior to the start of the trial. We will collect this data by observing the care of a random sample of patients. The sampling will be designed as a nested staircase design.

* Quality of life within seven days of discharge, and at 30 days and three months of arrival at the emergency department, measured by the oﬀicial and validated translations of the EQ5D3L. Data on this outcome will be collected in person if the patient is still in hospital, or by phone if the patient has been discharged. We will collect this data using a nested staircase design.
* Disability within seven days of discharge, and at 30 days and three months of ar- rival at the emergency department, assessed using the WHO Disability Assessment Schedule 2.0 (WHODAS 2.0). Data on this outcome will be collected in person if the patient is still in hospital, or by phone if the patient has been discharged. This data will also be collected using a nested staircase design.
* Return to work at 30 days and three months after arrival at the emergency de- partment. Data on this outcome will be collected in person if the patient is still in hospital, or by phone if the patient has been discharged. This data will also be collected using a nested staircase design.

## Handling of adverse and safety events

### Definitions

* + - 1. **Adverse event**

Any untoward medical occurrence in a clinical trial subject and, which does not necessar- ily have a causal relationship with the treatment, can be an unfavorable and unintended sign (including an abnormal laboratory discovery), symptom or disease temporally asso- ciated with the inclusion in the trial, whether or not related to the trial.

* + - 1. **Serious adverse event**

Any untoward medical occurrence in a trial participant that:

* + - * + leads to death
        + is life-threatening
        + requires inpatient hospitalization or prolongation of existing hospitalization
        + results in persistent or significant disability or incapacity
        + results in a congenital anomaly/malformation
      1. **Safety event**

Any unexpected serious complication that might occur as a consequence of the trial and that are not part of the natural history of trauma.

### Reporting and assessment of adverse and safety events

In alignment with other current trials including critically ill patients35, we will not collect adverse events or serious adverse events, because many of these events are expected in this patient population and we already collect many of these events, for example mortality, as part of our outcomes.

We will only report safety events, if they are life-threatening, prolong hospitalisation or result in meaningful harm to the participant. We cannot pre-define a comprehensive list of events that can be considered safety events, but will actively assess the presence of the following safety events:

* Prolonged mechanical ventilation (> 7 days)
* Initiation of renal replacement therapy
* Prolonged (> 2 days) or renewed (restart after at least 2 days without) use of vasopressors such as norepinephrine or vasopressin

These events are considered safety events because they suggest pulmonary, renal, septic or bleeding complications and an increase in their occurrence following ATLS® train- ing could indicate that the intervention is harmful. These events therefore need to be tracked during the standard care phase as well as the intervention phase, but will only be considered indicative of harm related to the intervention if they occur more often during the intervention phase than during the standard care phase.

We will also report any other safety events that we identify during the trial, and the reporting of such will have to be based on the intuition of the clinical research coordina- tors and local investigators. Examples of such safety events could include missed injuries or missed investigations, which could be suspected if certain injuries or investigations were identified or conducted more often during the standard care phase than during the intervention phase.

All safety events will be recorded in the Case Record Form (CRF) and reported to the trial management team within 24 hours of its occurrence. The trial management team will then assess if the event can be considered related to the trial or the intervention within 24 hours of it being reported. Events that are considered probably related will be reported immediately to the joint Trial Steering and Data Monitoring Committee.

### Follow up of safety events

All safety events should be followed up by the local investigator until they are fully evaluated.

## Statistics

### General principles

We will conduct all analysis by modified intention to treat. Clusters and observations within clusters will be considered exposed to the intervention after the date at which the cluster was scheduled to transition. All data will be included with the exception of the transition phases. We will not adjust for multiplicity of analyses because none of the secondary outcomes will be singularly more important. However, all secondary outcomes will be interpreted with due consideration for how all are affected by the intervention without putting any undue emphasis on a single outcome that might be statistically significant but where all others appear to have remained unchanged.

We will use a two-sided significance level of 5% and estimate 95% confidence intervals. The primary subgroup analyses will be based on geographical region because demonstrat- ing the consistency of any effect across multiple regions will enhance the generalisibility of the results[4](#_bookmark53). Additional subgroup analyses will include age across the groups older adolescents (15-19 years), young adults (20-24 years), adults (25-59 years), and older adults (60 years and older)36; sex; and the clinical cohorts blunt multisytem trauma, penetrating trauma, and severe isolated traumatic brain injury.

### Analysis models

There are a number of requirements for the analysis model. Firstly, all analysis will consider the clustered nature of the design. Secondly, as the trial has only 30 clusters, it will be essential that the model allows for a correction due to the small number of clusters. Thirdly, as the design is a stepped-wedge study, we will adjust for temporal confounding using categorical effects for period of the study (month). Full details on how each of these will be undertaken, with justification is provided below37.

For binary outcomes, a mixed effects binomial regression with a logit link will be used to estimate the odds ratio; and a binomial model with identity link used to estimate the risk difference. These models will be fitted using residual pseudo-likelihood estimation based on linearization with subject-specific expansion (RSPL). If the binomial model with the identity link does not converge then only a odds ratio will be reported.

4**Note:** Batches will not be based on regions because it will be logistically more feasible to include clusters from different regions in each batch.

We will include fixed effects for period and a fixed effect for intervention exposure. The primary analysis will allow for clustering by as a random cluster and random cluster by period effect. To correct the potential inflation of the type I error rate due to small number of clusters, a correction for a small number of clusters will be applied, but the correction that will be selected will be based on the best available evidence available closer to the time, and it may differ for the outcomes collected via the complete and incomplete designs. In a sensitivity analysis we will explore if models with more compli- cated correlation structures are a better fit to the data. These models are not being used as our primary analysis models as there is limited understanding as to when such mod- els will converge and how to choose between the various different correlation structures which might be plausible.

To this end we will additionally fit generalised linear mixed models (with same link functions and fixed effects as described above) to include a discrete time decay correlation structure including a random cluster effect with auto-regressive structure (AR(1)). To allow for the randomisation by batches, a different secular trend will be included for each batch (interaction between batch and period). For continuous, count and prevalence outcomes similar model-based approaches will be used but with appropriate links and distribution functions, using transformations where appropriate.

### Additional sensitivity analyses

To additionally explore if the fixed period effect is both parsimonious and adequate to represent the extent of any underlying secular trend, we will model the time effect using a spline function. Models will also be extended to include random cluster by intervention effects (with a non-zero covariance term) to examine if results are sensitive to the assumption of no intervention by cluster interaction. Models will also be extended to include an interaction between treatment and number of periods since first treated, to examine if there is any indication of a relationship between duration of exposure to the intervention and outcomes.

This will allow us to different lag effects (whereby it takes time for the intervention to become embedded within the culture before its impact can properly start to be realised); as well as weaning effects (whereby the effect of the intervention starts to decrease – or fade). This type of analysis attempts to disentangle how some clusters end up having a long exposure to the intervention and others have a much shorter exposure time. A fully adjusted covariate analysis will additionally adjust for a set of pre-specified individual- level covariates of known prognostic importance.

### Estimation and reporting of within cluster correlations

We will report time adjusted within-cluster correlations for all outcomes with 95% con- fidence intervals. We will report correlations from the different assumed correlation

structures (so we will report intra-cluster correlations (ICC); within and between-period correlations; and within-period correlations and exponential decay). As well as reporting correlations we will additionally report all variance components. For all outcomes we will report correlations on the latent scale (i.e. proportions scale for binary outcomes) as is appropriate to inform future sample size calculations.

### Sample size calculations

With 30 clusters across 6 batches and a total sample size of 4320 our study has ~90% power across different combinations of cluster autocorrelations (CAC) and intra-cluster correlations (ICC) to detect a reduction in the primary outcome of in-hospital mortal- ity within 30 days from 20% under standard care to 15% after ATLS® training (see Figure [3](#_bookmark59)). This effect is a conservative estimate and the reduction equals a risk ratio of 0.75, which would be clinically important while also being consistent with our pilot study and updated systematic review. We allowed for the clustered design and assumed an ICC of 0.02, but considered sensitivity across the range 0.01-0.0538,39, and a CAC of 0.9 but considered sensitivity across the range 0.8-1.0, based on our pilot study and current guidance40–42. We included the CAC to allow for variation in clustering over time. We assume that each cluster will contribute approximately 12 observations per month to the analysis, based on our previous work.

### Interim analysis

There will be one interim analyses after half of the batches have completed the trial. The interim analyses will be assessed by the joint Trial Steering and Data Monitoring Committee. The purposes of this interim analysis will be to:

* assess the trial’s feasibility and recommend stopping the trial if the trial is not feasible, for example if hospitals fail to adhere to the randomisation schedule or if there are substantial missing data in outcomes;
* compare characteristics across intervention conditions to monitor for differential recruitment/ascertainment between intervention and control.

## Quality control and quality assurance

The George Institute for Global Health - India will ensure proper conduct of the trial through quality control measures including on-site training of personnel, standard oper- ating procedures, ongoing quality metrics assessment, review of missing data and outliers, and round-the-clock availability of coordinating center personnel and Principal Investi- gators. The trial will strictly follow ICH GCP principles, Indian regulations, and George Institute procedures. The trial operations staff from the George Institute India will train local investigators, and trial site staff, before the trial, with continuous documentation




Figure 3: Power curves for different combinations of cluster autocorrelations (CAC) and intra-cluster correlations (ICC). **A)** Shows power curves assuming a reduction in the primary outcome of in-hospital mortality within 30 days from 20% under standard care to 15% after ATLS® training. **B)** Shows power curves assuming a reduction in the primary outcome from 10% under standard care to 7.5% after ATLS® training. Under this scenario, we would need to increase the sample size per month to around 30 observations to achieve 90% powere under most combinations of CAC and ICC.

in the site master file. All documentation will be stored securely and retained according to regulatory requirements.

## Quality assurance and oversight

The Trial Management Group and Trial Team, comprising key project leaders and man- agers, will play a pivotal role in ensuring the highest standards of quality assurance and effective sponsor oversight throughout the trial. These groups will be responsible for facilitating consistent communication, maintaining fidelity in study implementation, and overseeing the quality of data collection.

To achieve these objectives, the groups will implement a comprehensive communication plan and provide extensive training to site personnel. The training will cover not only the study protocol but also practical aspects of various systems, supplemented by both written and electronic materials designed to educate study and clinical emergency staff.

The trial’s quality assurance systems will be meticulously designed based on a thorough risk analysis. A key component of our quality assurance strategy will include the de- velopment and implementation of detailed operational manuals and regular meetings. These tools and interactions will ensure that all trial personnel will be used to uphold the trial’s quality standards.

Central to our oversight approach will be a comprehensive monitoring and auditing plan. This plan will be tailored based on the identified risks associated with the trial. Through these comprehensive measures, the trial management group, in conjunction with the hospital staff, will ensure that the trial is conducted with the utmost rigor, adhering to the highest standards of quality assurance and effective sponsor oversight.

## Monitoring

We will implement a multi-tiered monitoring strategy, including centralized data con- sistency checks, statistical monitoring, and selective on-site evaluations. Key integrity measures include source data verification, data entry validation, and regular audits. Any protocol deviations will be thoroughly documented, with serious breaches promptly ad- dressed to ensure data integrity. Monitors from coordinating centres will assist investiga- tors in maintaining high ethical, scientific, technical, and regulatory quality. Monitoring visits will review protocol adherence, participant recruitment, adverse event reporting, compliance with study procedures, and regulatory adherence. Regular remote monitor- ing of the web-based database will be conducted to ensure data integrity, using validation and consistency rules and regular data cleaning. The Trial Team and Trial Management Group will monitor baseline characteristics, opt-in consent rates and differential opt-in consent rates across trial arms, follow-up rates, CRF return and completeness rates, and safety data.

# Deviations, serious breaches and other reporting obligations

The responsible investigator shall, without delay, report to the sponsor any serious breaches and deviations from the trial protocol, ICH-GCP and other regulations that significantly and directly affect, or with high likelihood could affect, the subjects’ safety and integrity or the reliability and robustness of the data generated in the trial. The sponsor should assess the suspected serious breach and the consequences of deviations that have occurred. Minor deviations that do not affect subjects’ integrity or safety, nor significantly affect the trial’s scientific value, are documented in the trial documentation of the principal investigator and the sponsor and appropriate measures shall be taken. The deviations must be recorded in the clinical trial report.

# Audits and inspections

Authorized representatives for the sponsor and Competent Authorities (CA) may carry out audits or inspections at the trial site, including source data verification. The inves- tigator must ensure that all source documents are available for audits and inspections. The purpose of an audit or inspection is to systematically and independently review all trial-related activities and documents, to determine whether these activities were per- formed, registered, analyzed and reported correctly according to protocol, ICH- GCP and applicable regulations.

# Ethics

## Compliance to the protocol, ICH-GCP and regulations

The trial will be performed in compliance with this clinical trial protocol, the Declara- tion of Helsinki, ICH-GCP (Good Clinical Practice), and current national regulations governing this clinical trial. This is to ensure the safety and integrity of the trial subjects as well as the quality of the data collected.

## Ethical review of the trial

The final protocol will be submitted for ethical review at all participating hospitals, where possible, as well as the The George Institute for Global Health in India and Swedish Ethical Review Atuhortiy.

## Procedure for obtaining consent

In this trial, consent refers to data collection, as patients cannot opt out of the inter- vention. This is because the intervention is implemented at the cluster level, involving training physicians in ATLS®. It is unreasonable to expect these physicians to temporar- ily disregard their training. Patient participants will be included in this trial under the following modes of consent:

* Opt out consent for **routinely recorded data and measurement of adher- ence to ATLS® principles**. Consent for the collection of routinely recorded data, either through interviews or by extracting information from medical records, as well as for the measurement of adherence to ATLS® principles, will be presumed unless explicitly declined. This approach is justified because the trial is considered to pose minimal risk and because data collection will be non-invasive. Addition- ally, obtaining consent specifically for the measurement of adherence to ATLS® principles could interfere with the provision of care and cause undue stress for the patient and their representatives. Patients, or their legally authorized repre- sentatives, will be provided with written information about the study upon their arrival at the hospital. The variables assumed to be routinely recorded are listed in Section [13.2](#_bookmark73).
* Opt in consent and assent for **non-routinely recorded data**. Informed consent for non-routinely recorded data will be actively sought from patient participants or their legally authorized representative. For participants who are between 15 and 18 years of age we will obtain both the assent of the participant as well as the consent of their guardian or legally authorized representative. The clinical research coordinators will approach patient participants and their representatives after admission. The consent and assent will be written for patient participants who are admitted to the hospital and verbal for participants who are transferred or discharged before the clinical research coordinators have had an opportunity to approach them. The verbal consent will be audio recorded.
* Waiver of informed consent for patients who are unconscious or otherwise unable to provide consent and do not have a legally authorized representative. This group represents the most severly injured patients and they have to be included to make the trial representative of the entire population of trauma patients. Patients par- ticipants who regain consciousness will be informed about the study and asked for consent for collection of non-routinely recorded data.

## Data protection

All data will be handled according to the Indian Council of Medical Research’s guidelines and standard operating procedures of the George Institute for Global Health India on data security and protection. Trial data will be shared via the trial electronic CRF (eCRF) throughout the trial. The eCRF will be accessible via VPN with a two-factor

authentication and the data will be held on a secure server. All investigators and trial site staff involved in this trial must comply with the requirements of the ICMR Guidelines on data security and protection. The participant information sheet provided to participants, will inform them how:

* the trial data will be collected, used and disclosed;
* how trial data are stored to maintain confidentiality in accordance with national data legislation; and
* for verification of the data, representatives delegated by the sponsor, as well as relevant authorities, may require access to parts of medical records or trial records that are relevant to the trial, including the patient participant’s medical history.

# Insurances

The George Institute for Global Health, India is responsible for ensuring that any insur- ance cover required to cover the set-up, management and conduct of the study in India has been obtained. The George Institute for Global Health, India is also responsible for ensuring that India Sites have been obtained and/or will obtain insurance prior to the opening of the study in India and shall be maintained for the duration of the study and for an appropriate period thereafter. This includes being responsible for ensuring that there is appropriate insurance for the duration of the study to cover against claims for compensation by participants arising out of their participation in the trial in India. Compensation in case of injury or death will be provided by the George Institute for Global Health, India according to the regulations outlined in rules 39, 40 and 42 of the New Drugs and Clinical Rules (2019). x

# Substantial changes to the trial

Substantial changes to the signed clinical trial protocol are only possible through ap- proved protocol amendments and by agreement between the sponsor and the principal investigator.

# Collection, handling, and archiving of data

Clinical research coordinators will collect data using a paper based CRF (see Appendix Section [19.3](#_bookmark106)), which is then transferred to an eCRF. All trial data in the CRF must be extracted from and be consistent with the relevant source documents. The eCRF will be accessible to trial coordinators, data managers, the Investigators, Clinical Trial Monitors, Auditors, and Inspectors as required. All data will be registered, managed, and stored in a manner that enables correct reporting, interpretation, and verification. The complete

Trial Master File, as well as source documents, will be archived for at least 10 years after the trial is completed. Source data in the medical records system are stored and archived in accordance with national regulations. Metadata will be publicly accessible via a persistent DOI, and anonymised data will be released upon project completion. A detailed data management plan is available here [https://doi.org/10.5281/zenodo.77487](https://doi.org/10.5281/zenodo.7748764) [64](https://doi.org/10.5281/zenodo.7748764).

## Source data

The source data for each variable is given in Section [13.2](#_bookmark73). Whenever medical records are the source data, this includes imaging and lab reports. Whenever an interview is given as the source, the CRF will constitute the source data, as this is where the responses to questions will be recorded. The local investigator must keep source documents for each patient participant in the trial. A document describing what has been classified as source data in the trial (source data reference document) will be included in the Investigator Site File (ISF). The investigator must ensure that all source documents are accessible for monitoring and other quality control activities. Source data is further defined before trial start at each individual site and can, in cases where source data is not registered in another document, consist of the CRF. This should be decided in consultation with the monitor and clearly stated in the source data reference document. Access to trial-related documentation, such as patient participants’ medical records, CRFs, other source data and other trial documentation will be provided for monitoring and auditing purposes. Access will also be granted in the context of regulatory inspections.

## Variables

### Screening

* **Screening ID**
* **1. Date of screening**
* **2. Date of data entry**
* **1. Is the patient at least 15 years old?** Source: Medical record or interview
  1. Yes
  2. No
* **2. Did the patient present with a history of trauma defined as having any of the reasons listed in the International Classification of Diseases chapter XX as the reason for presenting? Please see https://icd.who.int/browse10/2019/en#/XX for a complete list of ICD-10 codes** Source: Medical record or interview
  1. Yes
  2. No
* **3. Did the trauma occur less than 48 hours before arrival to the hospi- tal?** Source: Medical record or interview
  1. Yes
  2. No
* **4. Was the patient admitted?** Source: Medical record
  1. Yes
  2. No
* **5. Did the patient die after arrival but before admission?** Source: Medical record
  1. Yes
  2. No
* **6. Was the patient transferred to another hospital for admission?** Source: Medical record
  1. Yes
  2. No
* **1. Did the patient present with isolated limb injury?** Source: Medical record
  1. Yes
  2. No
* **2. Was the patient directly admitted to a ward without being seen by a physician in the emergency department?** Source: Medical record
  1. Yes
  2. No

### Consent

* **1. Is this patient included under the waiver of informed consent because the patient is unconscious or otherwise unable to provide consent and do not have a legally acceptable representative?**
  1. Yes
  2. No
* **1. Did the participant/ or legally acceptable representative (LAR) pro- vided consent for collection of non-routinely recorded data**
  1. Yes
  2. No
* **2. Who gave consent for collection of non-routinely recorded data?**
  1. Patient participant
  2. Legally acceptable representative
* **3. Relation of LAR with the Participant**
* **4. Why was Legally acceptable representative (LAR) approached for consent for collection of non-routinely recorded data?**
  1. The participant is incapacitated because of the trauma
  2. The participant is younger than 18 years
* **5. Date when participant or legally acceptable representative (LAR) gave consent for collection of non-routinely recorded data?**
* **6. How did the participant or legally acceptable representative (LAR) consent for collection of non-routinely recorded data?**
  1. In writing
  2. Verbally
* **7. Date when the participant was reconsented?**
* **1. Did the minor give assent for collection of non-routinely recorded data?**
  1. Yes
  2. No
* **2. Date when the minor gave assent for collection of non-routinely recorded data.**
* **3. In case the minor refused to participate, date when minor refused**
* **1. Is the participant or LAR wants to opt out from study?**
  1. Yes
  2. No
* **2. Who opted-out of the routinely recorded data (in-hospital)?**
  1. Patient participant
  2. Legally acceptable representative (LAR)
* **3. Date when participant or legally acceptable representative (LAR) opted-out.**
* **4. Did the participant or legally acceptable representative (LAR) sug- gested to delete all the previously recorded data?**
  1. Yes
  2. No

### Consent withdrawn

* **1. Does the participant or legally acceptable representative (LAR) want to withdraw the consent?**
  1. Yes
  2. No
* **2. Date of consent withdrawal for follow-up data collection.**
* **3. Procedure(s) for which consent has been withdrawn**
  1. Data collection prior to withdrawal
  2. All data collection after withdrawal
  3. Both

### Baseline

* **1. Age in years** Source: Medical record of interview
* **2. Sex** Source: Medical record of interview
  1. Female
  2. Male
  3. Other
  4. Not known
* **3. Current marital status** Requires opt-in consent, not routinely recorded. Source: Interview
  1. Never married
  2. Currently married
  3. Separated
  4. Divorced
  5. Widowed
  6. Cohabiting
  7. Not known
* **4. Education level** Requires opt-in consent, not routinely recorded. Source: Interview
  1. Not attended school
  2. Primary school
  3. Secondary school
  4. Higher secondary school
  5. Graduate
  6. Post graduate and above
  7. Other
  8. Not known
* **5. If other, please specify** Requires opt-in consent, not routinely recorded. Source: Interview
* **6. Main work status** Requires opt-in consent, not routinely recorded. Source: Interview
  1. Paid work, such as daily wage earner, teacher, factory worker and government employee
  2. Self-employed, such as own your business or farming
  3. Non-paid work, such as volunteer or charity
  4. Student
  5. Keeping house/homemaker
  6. Retired
  7. Unemployed (health reasons)
  8. Unemployed (other reasons)
  9. Other
  10. No income
  11. Not known
* **7. If other, please specify** Requires opt-in consent, not routinely recorded. Source: Interview
* **8. Income level in INR per month** Requires opt-in consent, not routinely recorded. Source: Interview
  1. Below 10,000
  2. 10,001-20,000
  3. 20,001-30,000
  4. 30,001-50,000
  5. 50,001-80,000
  6. 80,001-1,00,000
  7. Above 1,00,000
  8. Not known
* **9. Mechanism of injury** Coded using ICD 10. Source: Medical record
* **10. Clinical Frailty Scale** Source: Medical record or treating physician
  1. 1. Very fit
  2. 2. Fit
  3. 3. Managing well
  4. 4. Living with very mild frailty
  5. 5. Living with mild frailty
  6. 6. Living with moderate frailty
  7. 7. Living with severe frailty
  8. 8. Living with very severe frailty
  9. 9. Terminally ill
  10. Not known
* **11. Comorbidities (Charlson Comorbidity Index)** Source: Medical record, treating physician or interview
  1. Myocardial infarction
  2. Congestive heart failure
  3. Peripheral vascular disease
  4. Cerebrovascular disease
  5. Dementia
  6. Chronic pulmonary disease
  7. Rheumatologic disease
  8. Peptic ulcer disease
  9. Liver disease
  10. Diabetes
  11. Hemiplegia or paraplegia
  12. Renal disease
  13. Malignancy
  14. Leukemia
  15. Lymphoma
  16. AIDS
  17. Not known
  18. None
* **12. Severity of liver disease** Source: Medical record, treating physician or interview
  1. Mild
  2. Moderate or severe
  3. Not known
* **13. Severity of diabetes** Source: Medical record, treating physician or interview
  1. Controlled
  2. Uncontrolled
  3. Not known
* **14. Severity of malignancy** Source: Medical record, treating physician or in- terview
  1. Localized
  2. Metastatic tumor
  3. Not known

### Prehospital

* **1. Date and time of injury** Source: Medical record of interview
* **2. Mode of transport to the participating hospital** Source: Medical record of interview
  1. Ambulance
  2. Police
  3. Private vehicle
  4. Walking
  5. Others
  6. Not known
* **3. If other, please specify** Source: Medical record of interview
* **4. Referred or transferred to the participating hospital from another hospital** Source: Medical record of interview
  1. Yes
  2. No
  3. Not known

### ATLS adherence

* **1. Airway patency checked** Source: Observation
  1. Yes
  2. No
* **1. Chest wall palpated** Source: Observation
  1. Yes
  2. No
* **2. Breath sounds checked** Source: Observation
  1. Yes
  2. No
* **3. Respiratory rate measured** Source: Observation
  1. Yes
  2. No
* **4. Saturation (SpO2) measured** Source: Observation
  1. Yes
  2. No
* **1. Heart rate measured** Source: Observation
  1. Yes
  2. No
* **2. Blood pressure measured** Source: Observation
  1. Yes
  2. No
* **3. Abdomen palpated** Source: Observation
  1. Yes
  2. No
* **4. Thighs palpated** Source: Observation
  1. Yes
  2. No
* **5. IV access obtained** Source: Observation
  1. Yes
  2. No
* **1. GCS checked** Source: Observation
  1. Yes
  2. No
* **2. Pupils checked** Source: Observation
  1. Yes
  2. No
* **1. Patients exposed for assessment**
  1. Yes
  2. No
* **2. Temperature measured** Source: Observation
  1. Yes
  2. No
* **1. Which airway interventions were performed?** Source: Observation
  1. None
  2. Manual airway procedure such as chin lift or jaw thrust
  3. Nasopharyngeal or Oropharyngeal airway inserted
  4. Supraglottic airway device
  5. Tracheal intubation
  6. Surgical airway
  7. Other
  8. Not known
* **2. If other airway Interventions given, specify**
* **3. Were airway interventions performed while minimising c-spine move- ment?** Source: Observation
  1. Yes
  2. No
  3. Not known
* **1. Which breathing interventions were performed?** Source: Observation
  1. None
  2. Oxygen applied
  3. Intracostal drain placement
  4. Other
  5. Not done
  6. Not known
* **2. If other breathing Interventions done, specify**
* **1. Which circulation interventions and adjuncts were performed?** Source: Observation
  1. None
  2. Control of external bleeding
  3. Fluid bolus
  4. Blood transfusion
  5. eFast
  6. Pelvic binder applied
  7. Reduction of highly displaced fracture
  8. Other
  9. Not known
* **2. If other circulation Interventions done, specify**
* **1. Which disability intervention was performed?** Source: Observation
  1. None
  2. Placement of definitive airway if the patient had a GCS of 8 or less
  3. Log Rolling
  4. Spine board during transportation
  5. Other
  6. Not known
* **2. If other disability interventions done, specify**
* **1. Which exposure intervention was performed?** Source: Observation
  1. None
  2. Covered with warmer or blanket
  3. Warm fluids administered
  4. Other
  5. Not known
* **2. If other exposure interventions done, specify**

### Emergency department

* **1. Date and time of arrival to the emergency department at the partic- ipating hospital** Source: Medical record of interview
* **2. First recorded systolic blood pressure (mmHg)** Source: Medical record
* **3. First recorded diastolic blood pressure (mmHg)** Source: Medical record
* **4. First recorded heart rate (beats per minute)** Source: Medical record
* **5. First recorded respiratory rate (breaths per minute)** Source: Medical record
* **6. First recorded Glasgow Coma Scale** Source: Medical record
* **7. First recorded body temperature (°C)** Source: Medical record
* **8. First recorded oxygen saturation (%)** Source: Medical record
* **9. Emergency department disposition** Source: Medical record
  1. Admitted
  2. Referred or transferred for admission
  3. Dead
  4. Others
  5. Not known
* **10. If other, please specify** Source: Medical record
* **11. Date and time of referral or transfer for admission** Source: Medical record

### Hospital

* **1. Date of admission to the participating hospital** Source: Medical record
* **1.1 Time of admission to the participating hospital** Source: Medical record
* **2. Type of admitting ward** Source: Medical record
  1. General surgery
  2. Orthopaedics
  3. Neurosurgery
  4. Intensive care unit
  5. High dependency unit
  6. Medicine
  7. Trauma ward
  8. Not known
* **3. Ward name or number** Source: Medical record
* **4. Admitted to intensive care unit during admission** Source: Medical record
  1. Yes
  2. No
  3. Not known
* **5. Date of first intensive care unit admission** Source: Medical record
* **5.1 Time of first intensive care unit admission** Source: Medical record
* **6. Date of first intensive care unit discharge** Source: Medical record
* **6.1 Time of first intensive care unit discharge** Source: Medical record
* **7. Hospital disposition** Source: Medical record
  1. Alive
  2. Dead
  3. Transferred for admission
  4. Not known
* **8. Was the patient transferred to another hospital for admission?** Source: Medical record
  1. Yes
  2. No
  3. Not known
* **9. Date of discharge or transfer from participating hospital** Source: Med- ical record
* **9.1 Time of discharge or transfer from participating hospital** Source: Med- ical record

### Surgery

* **1. Date of surgical procedure** A surgical procedure is defined as any procedure performed in the operating room, interventional dropdownlogy suite, or at the bedside, requiring general or regional anesthesia. Source: Medical record
* **1. Time of surgical procedure** A surgical procedure is defined as any procedure performed in the operating room, interventional dropdownlogy suite, or at the bedside, requiring general or regional anesthesia. Source: Medical record
* **2. Preoperative ASA score** Source: Medical record or treating physician
  1. 1. A normal healthy patient
  2. 2. A patient with mild systemic disease
  3. 3. A patient with severe systemic disease
  4. 4. A patient with severe systemic disease that is a constant threat to life
  5. 5. A moribund patient who is not expected to survive without the operation
  6. 6. A declared brain-dead patient whose organs are being removed for donor purposes
  7. 999. Not known
* **3. Description of procedure** Source: Medical record
* **4. Procedure coded according to SNOMED CT** Source: Medical record

### Imaging

* **1. Date and time of imaging** Source: Medical record
* **1.1 Time of imaging** Source: Medical record
* **2. Type of imaging** Source: Medical record
  1. Ultrasound
  2. X-ray
  3. Computed Tomography (CT)
  4. Magnetic Resonance Imaging (MRI)

### Transfusion

* **1. Date of transfusion** Source: Medical record
* **1.1 Time of transfusion** Source: Medical record
* **2. Type of blood product** Source: Medical record
  1. Packed red blood cells
  2. Platelets
  3. Fresh frozen plasma
  4. Whole blood
  5. Other
* **2.1 Other specify**
* **3. Number of units transfused** Source: Medical record

### Injury

* **1. Injury description** Source: Medical record
* **2. ICD 10 code** Coded using ICD 10. Source: Medical record
* **3. Injury source data** Source: Medical record
  1. Medical record
  2. X-ray report
  3. CT-report
  4. Surgical notes
* **4. Injury time**

### Individual mortality status

* **1. Is the patient dead?** Source: Medical record or interview
  1. Yes
  2. No
* **2. Date and time of death** Source: Medical record or interview

### Quality of life (EQ5D5L)

* **Date of filling this form**
* **First, I would like to ask you about MOBILITY. Would you say that:**

Requires opt-in consent, not routinely recorded. Source: Interview

* 1. You have no problems in walking about?
  2. You have slight problems in walking about?
  3. You have moderate problems in walking about?
  4. You have severe problems in walking about?
  5. You are unable to walk about?
* **Next, I would like to ask you about SELF-CARE. Would you say that:**

Requires opt-in consent, not routinely recorded. Source: Interview

* 1. You have no problems washing or dressing yourself?
  2. You have slight problems washing or dressing yourself?
  3. You have moderate problems washing or dressing yourself?
  4. You have severe problems washing or dressing yourself?
  5. You are unable to wash or dress yourself?
* **Next, I would like to ask you about USUAL ACTIVITIES, for example, work, study, housework, family or leisure activities. Would you say that:** Requires opt-in consent, not routinely recorded. Source: Interview
  1. You have no problems doing your usual activities?
  2. You have slight problems doing your usual activities?
  3. You have moderate problems doing your usual activities?
  4. You have severe problems doing your usual activities?
  5. You are unable to do your usual activities?
* **Next, I would like to ask you about PAIN OR DISCOMFORT. Would you say that:** Requires opt-in consent, not routinely recorded. Source: Interview
  1. You have no pain or discomfort?
  2. You have slight pain or discomfort?
  3. You have moderate pain or discomfort?
  4. You have severe pain or discomfort?
  5. You have extreme pain or discomfort?
* **Finally, I would like to ask you about ANXIETY OR DEPRESSION. Would you say that:** Requires opt-in consent, not routinely recorded. Source: Interview
  1. You are not anxious or depressed?
  2. You are slightly anxious or depressed?
  3. You are moderately anxious or depressed?
  4. You are severely anxious or depressed?
  5. You are extremely anxious or depressed?
* **I would now like you to tell me the point on this line where you would put your health TODAY.(Note to interviewer: mark the line at the point indicating the respondent’s health today.)** Requires opt-in consent, not routinely recorded. Source: Interview

### Disability (WHODAS 2.0)

* **Date of form filling**
* **1. Who are you interviewing?** Requires opt-in consent, not routinely recorded. Source: Interview
  1. Patient participant
  2. Patient representative
* **2. What is the relationship between the representative and the partic- ipant?** Requires opt-in consent, not routinely recorded. Source: Interview
  1. Husband or wife
  2. Parent
  3. Son or daughter
  4. Brother or sister
  5. Other relative
  6. Friend
  7. Professional carer
  8. Other (specify)
* **3. If other, please specify**
* **1. Standing for long periods such as 30 minutes?** Requires opt-in consent, not routinely recorded. Source: Interview
  1. None
  2. Mild
  3. Moderate
  4. Severe
  5. Extreme or cannot do
  6. None
  7. Mild
  8. Moderate
  9. Severe
  10. Extreme or cannot do
* **2. Taking care of your household responsibilities?** Requires opt-in consent, not routinely recorded. Source: Interview
  1. None
  2. Mild
  3. Moderate
  4. Severe
  5. Extreme or cannot do
* **3. Learning a new task, for example, learning how to get to a new place?**

Requires opt-in consent, not routinely recorded. Source: Interview

* 1. None
  2. Mild
  3. Moderate
  4. Severe
  5. Extreme or cannot do
  6. None
  7. Mild
  8. Moderate
  9. Severe
  10. Extreme or cannot do
* **4. How much of a problem did you have joining in community activities (for example, festivities, religious or other activities) in the same way as anyone else can?** Requires opt-in consent, not routinely recorded. Source: Interview
  1. None
  2. Mild
  3. Moderate
  4. Severe
  5. Extreme or cannot do
* **5. How much have you been emotionally affected by your health prob- lems?** Requires opt-in consent, not routinely recorded. Source: Interview
  1. None
  2. Mild
  3. Moderate
  4. Severe
  5. Extreme or cannot do
* **1. Concentrating on doing something for ten minutes?** Requires opt-in consent, not routinely recorded. Source: Interview
  1. None
  2. Mild
  3. Moderate
  4. Severe
  5. Extreme or cannot do
  6. None
  7. Mild
  8. Moderate
  9. Severe
  10. Extreme or cannot do
* **2. Walking a long distance such as a kilometre [or equivalent]?** Requires opt-in consent, not routinely recorded. Source: Interview
  1. None
  2. Mild
  3. Moderate
  4. Severe
  5. Extreme or cannot do
  6. None
  7. Mild
  8. Moderate
  9. Severe
  10. Extreme or cannot do
* **3. Washing your whole body?** Requires opt-in consent, not routinely recorded. Source: Interview
  1. None
  2. Mild
  3. Moderate
  4. Severe
  5. Extreme or cannot do
* **4. Getting dressed?** Requires opt-in consent, not routinely recorded. Source: Interview
  1. None
  2. Mild
  3. Moderate
  4. Severe
  5. Extreme or cannot do
  6. None
  7. Mild
  8. Moderate
  9. Severe
  10. Extreme or cannot do
* **5. Dealing with people you do not know?** Requires opt-in consent, not routinely recorded. Source: Interview
  1. None
  2. Mild
  3. Moderate
  4. Severe
  5. Extreme or cannot do
* **6. Maintaining a friendship?** Requires opt-in consent, not routinely recorded. Source: Interview
  1. None
  2. Mild
  3. Moderate
  4. Severe
  5. Extreme or cannot do
  6. None
  7. Mild
  8. Moderate
  9. Severe
  10. Extreme or cannot do
* **7. Your day-to-day work/school?** Requires opt-in consent, not routinely recorded. Source: Interview
  1. None
  2. Mild
  3. Moderate
  4. Severe
  5. Extreme or cannot do
* **2. Taking care of his or her household responsibilities?** Requires opt-in consent, not routinely recorded. Source: Interview
  1. None
  2. Mild
  3. Moderate
  4. Severe
  5. Extreme or cannot do
* **4. How much of a problem did he or she have joining in community activities (for example, festivities, religious or other activities) in the same way as anyone else can?** Requires opt-in consent, not routinely recorded. Source: Interview
  1. None
  2. Mild
  3. Moderate
  4. Severe
  5. Extreme or cannot do
* **5. How much has your relative been emotionally affected by his or her health condition?** Requires opt-in consent, not routinely recorded. Source: Interview
  1. None
  2. Mild
  3. Moderate
  4. Severe
  5. Extreme or cannot do
* **3. Washing his or her whole body?** Requires opt-in consent, not routinely recorded. Source: Interview
  1. None
  2. Mild
  3. Moderate
  4. Severe
  5. Extreme or cannot do
* **5. Dealing with people he or she does not know?** Requires opt-in consent, not routinely recorded. Source: Interview
  1. None
  2. Mild
  3. Moderate
  4. Severe
  5. Extreme or cannot do
* **7. His or her day-to-day work/school?** Requires opt-in consent, not routinely recorded. Source: Interview
  1. None
  2. Mild
  3. Moderate
  4. Severe
  5. Extreme or cannot do
* **1. Overall, in the past 30 days, how many days were these diﬀiculties present?** Requires opt-in consent, not routinely recorded. Source: Interview
* **2. In the past 30 days, for how many days were you totally unable to carry out your usual activities or work because of any health condition?** Requires opt-in consent, not routinely recorded. Source: Interview
* **3. In the past 30 days, not counting the days that you were totally unable, for how many days did you cut back or reduce your usual ac- tivities or work because of any health condition?** Requires opt-in consent, not routinely recorded. Source: Interview

### Return to work

* **Date of form filling**
* **1. Did participant returned to work?**
  1. Yes
  2. No
* **2. Date and time of return to work** Requires opt-in consent, not routinely recorded. Source: Interview
* **3. Work status** Requires opt-in consent, not routinely recorded. Source: Inter- view
  1. Paid work
  2. Self-employed, such as own your business or farming
  3. Non-paid work, such as volunteer or charity
  4. Student
  5. Keeping house/homemaker
  6. Not known

### Safety events

* **1. Date reported to trial management team of safety event**
* **2. Type of safety event** Source: Medical record or treating physician
  1. Prolonged mechanical ventilation (> 7 days)
  2. Initiation of renal replacement therapy
  3. Prolonged (> 2 days) use of vasopressors such as norepinephrine or vasopressin
  4. Renewed (restart after at least 2 days without) use of vasopressors such as norepinephrine or vasopressin
  5. Other
* **3. Elaborate on other safety event** Source: Medical record or treating physi- cian
* **4. Investigator assessment of safety event** Source: Investigator

### End of study

* **1. What is the reason for the end of study?**
  1. Completed follow up
  2. Lost to follow up
  3. Death
  4. Discharge and no consent for follow up
  5. Opt-out from routinely recorded (in-hospital) data collection and no consent for follow-up
  6. Opt-out from routinely recorded (in-hospital) data collection and withdrawn consent for follow-up
* **2. Date and time of end of study**

# Trial organisation




Figure 4: Trial organisation overview.

Trial management and oversight is governed by three trial committees and groups: the Trial Team (TT), the Trial Management Group (TMG), the joint Trial Steering and Data Monitoring Committee (SDMC). These groups and their relationships are briefly described in Figure [4](#_bookmark93). Details about each committee and group are available in their respective charter.

## Trial team

**Responsibility**

To run the trial on a day-to-day basis, maintain trial databases, randomise clusters, ensuring complete and correct data, preparing reports for meetings (including those of the TMG and SDMC) and dealing with research governance and, if appropriate, regulatory matters.

**Composition**

Includes the project manager, clinical research associates, principal investigator and co- investigators as needed.

**Relationships**

Reports to the TMG and SDMC. Operationalises decisions made by the TMG.

**Meeting frequencies**

As often as needed, often weekly or bi-weekly.

## Trial Management Group (TMG)

**Responsibility**

To manage the trial, including its clinical and practical aspects.

**Composition**

Includes members with broad expertise appropriate to the trial. The TMG will be chaired by the Principal Investigator.

**Relationships**

Receives reports from TT. Provides input to the SDMC. Implements decisions made by the SDMC.

**Meeting frequencies**

Monthly to every six months.

## Joint Trial Steering and Data Monitoring Committee (SDMC)

**Responsibility**

The SDMC’s responsibility is to oversee the trial, review results of interim analyses and safety events reported by the TMG, and review trial data for each batch, assessing data quality, completeness, cluster performance in recruitment and loss to follow-up rates, and external factors affecting trial validity, safety, or ethics. This committee also offer guidance to the TMG.

**Composition**

A majority of independent members, including a chair and three additional external experts specializing in the clinical area, biostatistics, and a community or patient rep- resentative, as well as and a minority of members with a direct interest in the trial, including the principal investigator. The chair should be independent of the trial, and the coordinating institutions Karolinska Institutet and The George Institute for Global Health.

**Relationships**

Receives reports from the trial team and TMG.

**Meeting frequencies**

After the completion of each batch, but may be more frequent if needed.

# Funding

* Swedish Research Council (reg. no. 2023-03128)
* Laerdal Foundation (reg. no. 2023-0297)

# Special considerations

## Funding

This trial is not yet fully funded. The Trial Management Group has decided to proceed with the trial with the expectation that additional funding will be secured. The Trial Steering Committee will be informed of the funding status at each meeting. If funding is not secured, the trial will be stopped. This will likely result in an underpowered trial. The justification for this decision is that the intervention is considered standard of care in many countries and the data collection is considered minimal risk. There is therefore a very small risk of harm to patient participants, but a potential direct benefit to those patient participants who receive the intervention. The benefit-risk ratio is therefore considered to be favourable, even in the case of an underpowered trial.

## Potential amendments

There are ongoing discussions about re-framing the trial as a hybrid effectiveness- implementation trial and include a cost-effectiveness analysis. This would involve adding additional data collection to assess the implementation and costs of the intervention. This would involve additional funding and amended ethical approvals.

# Notification of trial completion, reporting, and publication

The trial will be reported to the Funders within a year of completion. The results of the trial will also be prepared as manuscripts for publication. Authorship on trial manuscripts will be based on the International Committee of Medical Journal Editors (ICMJE) criteria43:

* Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
* Drafting the work or reviewing it critically for important intellectual content; AND
* Final approval of the version to be published; AND
* Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

In addition to being accountable for the parts of the work done, an author should be able to identify which co-authors are responsible for specific other parts of the work. In addition, authors should have confidence in the integrity of the contributions of their co-authors.

The most recent version of the ICMJE criteria will be adhered to. We will also use the ICMJE criteria for non-author contributorship.

Before work on a trial manuscript is initiated, a writing group will be formed and first and last authors will be designated. This writing group will be formed by discussion in the Trial Management Group.

# References

1. GBD 2019 Diseases and Injuries Collaborators. Injuries—level 1 cause. *The Lancet* **396**, (2020).
2. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the global burden of disease study 2019. *The Lancet* **396**, 1204–1222 (2020).
3. Rauf, R. *et al.* Changes in the temporal distribution of in-hospital mortality in severely injured patients—an analysis of the TraumaRegister DGU. *PLOS ONE* **14**, e0212095 (2019).
4. Roy, N. *et al.* Learning from 2523 trauma deaths in india- opportunities to prevent in-hospital deaths. *BMC Health Serv Res* **17**, (2017).
5. Callcut, R. A. *et al.* The why and how our trauma patients die: A prospective multicenter western trauma association study. *J Trauma.* **86**, 864–870 (2019).
6. Ghorbani, P. *et al.* Analysis of preventable deaths and errors in trauma care in a scandinavian trauma level-i centre. *Acta Anaesthesiol Scand* **62**, 1146–1153 (2018).
7. Mohammad, A. *et al.* Educational and clinical impact of advanced trauma life support (ATLS) courses: A systematic review. *World J. Surg.* **38**, 322–329 (2013).
8. Jayaraman, S. *et al.* Advanced trauma life support training for hospital staff.

*Cochrane Database Syst Rev* (2014).

1. Kadhum, M. *et al.* Are primary trauma care (PTC) courses beneficial in low- and middle-income countries - a systematic review. *Injury* **51**, 136–141 (2020).
2. Jin, J. *et al.* Effectiveness of quality improvement processes, interventions, and structure in trauma systems in low- and middle-income countries: A systematic review and meta-analysis. *World J. Surg.* **45**, 1982–1998 (2021).
3. McIver, R. *et al.* Effect of trauma quality improvement initiatives on outcomes and costs at community hospitals: A scoping review. *Injury* **55**, 111492 (2024).
4. Committee on Trauma. *Advanced trauma life support® student course manual*. (American College of Surgeons, 2018).
5. American College of Surgeons. *Resources for optimal care of the injured patient*. (American College of Surgeons, 2022).
6. Ali, J. *et al.* Demonstration of acquisition of trauma management skills by senior medical students completing the ATLS program. *J Trauma.* **38**, 687–691 (1995).
7. Ali, J. *et al.* Teaching effectiveness of the advanced trauma life support program as demonstrated by an objective structured clinical examination for practicing physicians. *World J. Surg.* **20**, 1121–1126 (1996).
8. Ali, J. *et al.* Comparison of performance of interns completing the old (1993) and new interactive (1997) advanced trauma life support courses. *J Trauma.* **46**, 80–86 (1999).
9. Putra, A. B. *et al.* Impact of Advanced Trauma Life Support Training for Im- proving Mortality Outcome: A Systematic Review and Meta-analysis. *The New Ropanasury Journal of Surgery* **8**, (2023).
10. Vestrup, J. A. *et al.* Impact of advanced trauma life support training on early trauma management. *Am J Surg* **155**, 704–707 (1988).
11. Ariyanayagam, D. C. *et al.* The impact of the ATLS course on traﬀic accident mortality in trinidad and tobago. *West Indian Med J* **41**, 72–74 (1992).
12. Ali, J. *et al.* Trauma outcome improves following the advanced trauma life support program in a developing country. *J Trauma* **34**, 890–899 (1993).
13. Olson, C. J. *et al.* Influence of trauma system implementation on process of care delivered to seriously injured patients in rural trauma centers. *Surgery* **130**, 273–279 (2001).
14. Olden, G. D. J. van *et al.* Clinical impact of advanced trauma life support. *Am J Emerg Med* **22**, 522–525 (2004).
15. Wang, P. *et al.* Comparison of severe trauma care effect before and after advanced trauma life support training. *Chin J Traumatol* **13**, 341–344 (2010).
16. Drimousis, P. G. *et al.* Advanced trauma life support certified physicians in a non trauma system setting: Is it enough? *Resuscitation* **82**, 180–184 (2011).
17. Hashmi, Z. G. *et al.* Hospital-based trauma quality improvement initiatives. *J Trauma* **75**, 60–68 (2013).
18. Petroze, R. T. *et al.* Can focused trauma education initiatives reduce mortality or improve resource utilization in a low-resource setting? *World J. Surg.* **39**, 926–933 (2014).
19. Giovanni Bellanova, R. B., Francesco Buccelletti. How formative courses about damage control surgery and non-operative management improved outcome and survival in unstable politrauma patients in a mountain trauma center. *Annali italiani di chirurgia* **87**, 68–74 (2016).
20. Gerdin Wärnberg, M. *et al.* A pilot multicentre cluster randomised trial to com- pare the effect of trauma life support training programmes on patient and provider outcomes. *BMJ Open* **12**, e057504 (2022).
21. Hemming, K. *et al.* The stepped wedge cluster randomised trial: Rationale, design, analysis, and reporting. *BMJ* **350**, h391–h391 (2015).
22. Hemming, K. *et al.* Reflection on modern methods: When is a stepped-wedge cluster randomized trial a good study design choice? *Int J Epidemiol* **49**, 1043– 1052 (2020).
23. Kasza, J. *et al.* The batched stepped wedge design: A design robust to delays in cluster recruitment. *Stat Med* **41**, 3627–3641 (2022).
24. Harris, P. A. *et al.* Research electronic data capture (REDCap)–a metadata- driven methodology and workflow process for providing translational research informatics support. *Journal of Biomedical Informatics* **42**, 377–381 (2009).
25. Harris, P. A. *et al.* The REDCap consortium: Building an international commu- nity of software platform partners. *Journal of Biomedical Informatics* **95**, 103208 (2019).
26. Aukstakalnis, V. *et al.* Impact of video recordings review with structured de- briefings on trauma team performance: A prospective observational cohort study. *European Journal of Trauma and Emergency Surgery: Oﬀicial Publication of the European Trauma Society* (2024).
27. Nielsen, Niklas. Sedation, Temperature and Pressure after Cardiac Arrest and Resuscitation – the STEPCARE trial. (2023).
28. Diaz, T. *et al.* A call for standardised age-disaggregated health data. *The Lancet Healthy Longevity* **2**, e436–e443 (2021).
29. Li, F. *et al.* Mixed-effects models for the design and analysis of stepped wedge cluster randomized trials: An overview. *Stat Methods Med Res* **30**, 612–639 (2020).
30. Campbell, M. K. *et al.* Determinants of the intracluster correlation coeﬀicient in cluster randomized trials: The case of implementation research. *Clinical Trials* **2**, 99–107 (2005).
31. Eldridge, S. M. *et al.* How big should the pilot study for my cluster randomised trial be? *Stat Methods Med Res* **25**, 1039–1056 (2015).
32. Hemming, K. *et al.* A tutorial on sample size calculation for multiple-period cluster randomized parallel, cross-over and stepped-wedge trials using the shiny CRT calculator. *Int J Epidemiol* **49**, 979–995 (2020).
33. Martin, J. *et al.* Intra-cluster and inter-period correlation coeﬀicients for cross- sectional cluster randomised controlled trials for type-2 diabetes in UK primary care. *Trials* **17**, (2016).
34. Korevaar, E. *et al.* Intra-cluster correlations from the CLustered OUtcome dataset bank to inform the design of longitudinal cluster trials. *Clinical Trials* **18**, 529– 540 (2021).
35. ICMJE | Recommendations | Defining the Role of Authors and Contributors.

# Appendices

## Initial hospital screening instrument

**Screening call**

*Page 1*

This form is for screening potentially eligible clusters for the ATLS vs standard care trial. Please fill it in while talking to the hospital representative. Thank you so much for helping with this task!

Please complete the questions below.

Synopsis Title Effects of Advanced Trauma Life Support® Training Compared to Standard Care on Adult Trauma Patient Outcomes: A Cluster Randomised Trial

Rationale Trauma is a massive global health issue. Many training programmes have been developed to help physicians in the initial management of trauma patients. Advanced Trauma Life Support® (ATLS®) is the most popular of these programmes and have been used to train over one million physicians worldwide. Despite its widespread use, there are no controlled trials showing that ATLS® improves patient outcomes. Multiple systematic reviews emphasise the need for such trials.

Aim To compare the effects of ATLS® training with standard care on outcomes in adult trauma patients. Primary Outcome In-hospital mortality within 30 days of arrival at the emergency department.

Trial Design Batched stepped-wedge cluster randomised trial in India.

Trial Population Adult trauma patients presenting to the emergency department of a participating hospital. Sample Size 30 clusters and 4320 patients.

Eligibility Criteria

Cluster will be hospitals with a baseline admission rate of at least 400 patients with trauma per year or 35 patients with trauma per month for at least the last six months, that provide emergency surgical and orthopaedic services around the clock, and where no more than 25% of initial trauma care providers trained in a formalised trauma life support training programme.

Patients will be at least 15 years old, who present to the emergency department of participating hospitals with a history of trauma occuring less than 48 hours before arrival, and who are admitted or die between and admission, or who are transferred from the emergency department of a participating hospital to another hospital for admission.

Intervention The intervention will be ATLS® training, a proprietary 2.5 day course teaching a standardised approach to trauma patient care using the concepts of a primary and secondary survey. Physicians will be trained in an accredited ATLS® training facility in India.

Ethical Considerations In-hospital data collection will be conducted under a waiver of informed consent. Patients will be informed about the trial and their right to opt out of data collection. Patients will be informed that they can withdraw their data from the trial at any time.

Trial Period 2024-10-01 to 2029-10-01

**Hospital details**

Hospital name and address

*58 of* [*101*](#_bookmark107)

20/12/2023 08:14 projectredcap.org

*Page 2*

**Eligibility assessment**

Does the hospital admit trauma patients? Yes No

Is the hospital representative interested in Yes

potentially participating? No

(Comment: )

If the hospital representative is not interested in participating then you can go ahead and submit the form.

How many trauma patients aged 15 years or older, < 30

excluding patients with isolated limb injuries, are 30-60

admitted each month? > 60

Not sure (Comment: )

Does the hospital provide emergency surgery and Yes

orthopaedic services around the clock? No

(Comment: )

Out of the physicians involved in the initial Yes

resuscitation of trauma patients, are less than 25% No

trained in a formalised trauma life support training (Comment (like name of other training programme): programme like ATLS or Primary Trauma Care? )

Unfortunately, the hospital does not fulfil the eligibility criteria and you may go ahead and submit the form.

The hospital fulfills the cluster eligibility criteria. Please enter the hospital representative's contact details: Name E-mail Phone number

Before you can proceed to fill in descriptive information about the potential cluster, please confirm that the contact details are complete:

**Cluster descriptive information**

Out of the patients with trauma who present to the < 20% emergency department, what percentage are referrals or 20-50% transfers from other hospitals? 51-80%

> 80%

Not sure (Comment: )

Out of the patients with trauma who are admitted, what < 10% percentage are transferred to other hospitals? 10-20%

21-30%

>30%

Not sure (Comment: )

20/12/2023 08:14 projectredcap.org

Who performs the initial resuscitation of trauma  Casualty medical officers

patients as they arrive to the hospital?  Emergency medicine residents  Surgical residents

 Not sure (Comment: )

How many CMOs work in the emergency department? < 10

10-20

This question is here to help us estimate the number 21-30

of people we will need to train. > 30

Not sure (Comment: )

How many emergency medicine/general surgery residents < 10 are admitted each year? 10-20

21-30

This question is here to help us estimate the number > 30

of people we will need to train. Not sure (Comment: )

What specialities are available around the clock to  General surgery

care for trauma patients?  Orthopaedics

 Neurosurgery

 Vascular surgery

 Interventional radiology  Emergency medicine

 Not sure (Comment: )

What facilities are available around the clock?  X-ray

 Ultrasound/FAST  CT

 MRI

 Blood bank  Not sure

(Comment: )

How many beds does the hospital have? < 250 250-500

501-750

751-1000

>1000

Not sure (Comment: )

How many ICU beds does the hospital have? No ICU beds 1-10

11-20

21-30

> 30

Not sure (Comment: )

How many dedicated trauma beds does the hospital have? No dedicated trauma beds

1-10

11-20

21-30

> 30

Not sure (Comment: )

20/12/2023 08:14 projectredcap.org

*Page 4*

Please submit the form once you have completed all questions above.

20/12/2023 08:14 projectredcap.org

## In-depth hospital screening interview instrument

**Hospital screening interview for the ATLS vs standard care trial**

*Page 1*

This is the screening interview form for the Advanced Trauma Life Support® vs Standard Care trial planned by Karolinska Institutet along with The George Institute. You have expressed preliminary interest inparticipating in this trial. We are undertaking this hospital screening interview inorder to assess whether the study could be conducted at your hospital. We appreciate your efforts to answer as many of these questions as possible and we will follow up on your responses and any questions you may have in a separate call. Thank you!

**Synopsis Effects of Advanced Trauma Life Support® Training Compared to Standard Care on Adult Trauma Patient Outcomes: A Cluster Randomised Trial Rationale Trauma is a massive global health issue. Many training programmes have been developed to help physicians in the initial management of trauma patients. Among these programmes, Advanced Trauma Life Support® (ATLS®) is the most popular, having trained over one million physicians worldwide. Despite its widespread use, there are no controlled trials showing that ATLS® improves patient outcomes. Multiple systematic reviews emphasise the need for such trials.**



**Aim To compare the effects of ATLS® training with standard care on outcomes in adult trauma patients.**

**Primary Outcome All-cause mortality within 30 days of arrival at the emergency department.**

**Trial Design Batched stepped-wedge cluster randomised trial in India.**

**Trial Population Adult trauma patients presenting to the emergency department of a participating hospital.**

**Sample Size 30 clusters and 4320 patients.**

**Eligibility Criteria**

**Hospitals are secondary or tertiary hospitals in India that admit or refer/transfer for admission at least 400 patients with trauma per year.**

**Clusters are one or more units of physicians providing initial trauma care in the emergency department of tertiary hospitals in India.**

**Patients participants are adult trauma patients who presents to the emergency department of participating hospitals and are admitted or transferred for admission.**

**Intervention The intervention will be ATLS® training, a proprietary 2.5 day course teaching a standardised approach to trauma patient care using the concepts of a primary and secondary survey. Physicians will be trained in an accredited ATLS® training facility in India.**

**Ethical Considerations We will use an opt-out consent approach, in which consent is presumed unless actively declined. Note that consent here refers to consent to data collection, as it will not be possible for patients to opt out from being subjected to the intervention. This approach is justified because the trial can be considered to involve only minimal risk and the data**

22/02/2024 05:51 projectredcap.org

**collection is non-invasive and mostly involve extracting routinely collected data from medical records. Patient participants will be informed about the study and their right to opt out once they are admitted or telephonically if they are transferred. Patients will be informed that they can withdraw their data from the trial at any time before final analysis of the data.**

**Trial Period October 1, 2024, to September 30, 2029**

**Hospital details [hospital\_address]**

**Contact person details Name [contact\_name]**

**E-mail [contact\_email]**

**Phone number [contact\_phone\_number]**

Will you [contact\_name] also be the site investigator? Yes No

**Investigator details**

Please enter the name and contact details of the site investigator

Name E-mail

Phone number

Please enter these additional investigator details

Designation Specialization

State Medical Council registration number

Is the investigator trained in International Council Yes

for Harmonisation, Guideline for Good Clinical No Practice (ICH GCP)?

Will there be a co-investigator at your site? Yes No

Will you [contact\_name] be the co-investigator? Yes No

Please enter the name and contact details of the site investigator

Name E-mail

Phone number

*Page 3*

Please enter these additional co-investigator details

Designation Specialization

State Medical Council registration number

Is the co-investigator trained in International Yes

Council for Harmonisation, Guideline for Good Clinical No Practice (ICH GCP)?

**Ethical review details**

Does your hospital have an ethics committee registered Yes with CDSCO? No

Please enter the ethics committee registration number

In the next three months when is your IEC meeting up?

What is the expected timeline for ethics review at your site?

In which languages do you think the consent form should be translated, considering the languages spoken

by the potential participants treated at your hospital?

**Departmental logistics**

Does your hospital require any additional departmental review besides the ethics? Can you please elaborate on

that review?

Are there any potential logistical issues which may interfere with set up or running ofthis project at

your site?

(E.g. contract review, adequate space, lack of resources etc.)

What is the expected timeline for contract review,

negotiations and execution (in days)?

What is the maximum expected timeline?

22/02/2024 05:51 projectredcap.org

*Page 4*

**Initial trauma care**

How do patients typically arrive to your hospital?

Who are involved in the management of trauma patients in the emergency department?

What happens when additional expertise is needed?

What is the role of the casualty medical officers?

Are physicians organised in units?

How big are those units?

How are those units composed in terms of residents and faculty?

How often do the units rotate?

How many units are there working in the emergency department?

How many trauma patients aged 15 years or older are admitted per day, excluding patients with isolated limb injuries and those who are admitted directly to the ward?

**Intervention and patient inclusion**

How many patients do you think you could include in to the proposed trial per month? (We need to include at least 12 patients per month)

What is the basis of your patient enrollment estimate?

(For example database review, emergency department record, review of patient records, other)

Do you see any problems with including 12 patients per month at your site? Can you please elaborate on those problems?

22/02/2024 05:51 projectredcap.org

All hospitals in this trial will receive the intervention. The intervention is that we will train

approximately 10 physicians providing initial trauma

care in ATLS in your hospital. Who do you think we (Surgical residents? Emergency medicine residents? should train to maximise the effect? Casualty medical officers? Someone else??)

The time point when the training will be implemented will be randomised, but there will be a minimum of

three months between the start of the data collection and the training. The training will happen during a

one month long "transition period". How long notice do you need to plan the participation of the physicians from your hospital?

Are you aware of any plans to train providers in any formalised trauma life support training programme

during the next few years?

Are you aware of any plans to implement other interventions or changes that may radically change how

you treat trauma patients at your site?

(For example building a trauma centre, building a new emergency department, shifting the CT)

If we would like to visit your hospital to observe

trauma care delivery in the emergency department and

talk to providers, how can that be arranged?

**General**

How are the patient medical records organised at your  Hard-copy site?  Electronic

 Not sure

Do you currently have any competing studies or are you committed to new competing studies?

Do you have access to a computer with high-speed Yes

internet access? No

Do you currently have the necessary study team including research coordinator and co-investigators to conduct this study? Can you please elaborate on the composition and experience of that team?

What are your expectations of this trial?

Do you have any questions or comments regarding this trial?

Are you interested in participating in this trial? Yes No

22/02/2024 05:51 projectredcap.org

*Page 6*

If you have any questions, feel free to contact Martin Gerdin Wärnberg [(martin.gerdin@ki.se),](mailto:(martin.gerdin@ki.se) Monty Khajanchi [(monta32@gmail.com)](mailto:(monta32@gmail.com) or Samriddhi Ranjan [(sranjan@georgeinstitute.org.in)](mailto:(sranjan@georgeinstitute.org.in)

22/02/2024 05:51 projectredcap.org

## Case Record Form

**Screening V1.0.01.10.24**

*ATLS*

*Page 1*

Screening ID

1. Date of screening
2. Date of data entry

**Inclusion criteria**

1. Is the patient at least 15 years old? Yes No

(Source: Medical record or interview)

1. Did the patient present with a history of trauma Yes

defined as having any of the reasons listed in the No

International Classification of Diseases chapter XX as (Source: Medical record or interview) the reason for presenting?

Please see https://icd.who.int/browse10/2019/en#/XX for a complete list of ICD-10 codes

1. Did the trauma occur less than 48 hours before Yes

arrival to the hospital? No

(Source: Medical record or interview)

1. Was the patient admitted? Yes

No

(Source: Medical record)

1. Did the patient die after arrival but before Yes

admission? No

(Source: Medical record)

1. Was the patient transferred to another hospital for Yes

admission? No

(Source: Medical record)

**Exclusion criteria**

1. Did the patient present with isolated limb injury? Yes No

(Source: Medical record)

1. Was the patient directly admitted to a ward without Yes being seen by a physician in the emergency department? No

(Source: Medical record)

15-11-2024 10:47am projectredcap.org

*Page 2*

**Eligibility**

The patient is not eligible for inclusion.

15-11-2024 10:47am projectredcap.org

**Consent V1.0.01.10.24**

*ATLS*

*Page 3*

Study Consent

In this trial, consent refers to consent for data collection. It is not possible for patients to opt out from being subjected to the intervention, as the intervention is delivered at the cluster level. Patient participants will be included in this trial under the following modes of consent:

* Opt-out consent for collection of routinely recorded data
* Opt-in consent and assent for non-routinely recorded data, including but not restricted to Quality of Life (EQ5D5L), Disability (WHODAS 2.0) and Return to Work.
* Waiver of informed consent for patients who are unconscious or otherwise unable to provide consent and do not have a legally acceptable representative.

When possible, all patient participants must be approached and provided with information about the study, the option to opt out, and consent for collection of non-routinely recorded data.

**Section I: Consent Wavier**

**Please note that the consent for the collection of the routinely recorded data (in-hospital) will be presumed unless actively declined by the participant/ legally acceptable representative (LAR), using the opt-out form. Information for all forms except for baseline characteristics (marital and work status, education and income), follow-up (Quality of Life (EQ5D5L), Disability (WHODAS 2.0) and Return to Work) will be presumed, unless opted-out.**

1. Is this patient included under the waiver of Yes informed consent because the patient is unconscious or No otherwise unable to provide consent and do not have a

legally acceptable representative?

**Section II: Opt in consent for follow up data collection**

1. Did the participant/ or legally acceptable Yes

representative (LAR) provided consent for collection No of non-routinely recorded data

1. Who gave consent for collection of non-routinely Patient participant

recorded data? Legally acceptable representative

1. Relation of LAR with the Participant
2. Why was Legally acceptable representative (LAR)  The participant is incapacitated because of the approached for consent for collection of non-routinely trauma

recorded data?  The participant is younger than 18 years

1. Date when participant or legally acceptable representative (LAR) gave consent for collection of non-routinely recorded data?

15-11-2024 10:47am projectredcap.org

*Page 4*

1. How did the participant or legally acceptable In writing

representative (LAR) consent for collection of Verbally non-routinely recorded data?

1. Date when the participant was reconsented?

**Section III: Assent form**

1. Did the minor give assent for collection of Yes

non-routinely recorded data? No

1. Date when the minor gave assent for collection of non-routinely recorded data.
2. In case the minor refused to participate, date when minor refused

**Section IV: Opt out form**

1. Is the participant or LAR wants to opt out from Yes

study? No

1. Who opted-out of the routinely recorded data Patient participant

(in-hospital)? Legally acceptable representative (LAR)

1. Date when participant or legally acceptable representative (LAR) opted-out.
2. Did the participant or legally acceptable Yes

representative (LAR) suggested to delete all the No previously recorded data?

15-11-2024 10:47am projectredcap.org

**Consent\_Withdrawn V1.0.01.10.24**

*ATLS*

*Page 5*

**Consent withdrawal**

1. Does the participant or legally acceptable Yes

representative (LAR) want to withdraw the consent? No

1. Date of consent withdrawal for follow-up data collection.
2. Procedure(s) for which consent has been withdrawn Data collection prior to withdrawal

All data collection after withdrawal Both

15-11-2024 10:47am projectredcap.org

**Baseline V1.0.01.10.24**

*ATLS*

*Page 6*

1. Age in years

(Source: Medical record of interview)

1. Sex Female

Male Other

Not known

(Source: Medical record of interview)

1. Current marital status Never married

Currently married Separated Divorced Widowed Cohabiting

Not known

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. Education level Not attended school

Primary school Secondary school Higher secondary school Graduate

Post graduate and above Other

Not known

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. If other, please specify

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. Main work status  Paid work, such as daily wage earner, teacher, factory worker and government employee

Self-employed, such as own your business or farming Non-paid work, such as volunteer or charity

Student

Keeping house/homemaker Retired

Unemployed (health reasons) Unemployed (other reasons) Other

No income Not known

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. If other, please specify

(Requires opt-in consent, not routinely recorded. Source: Interview)

15-11-2024 10:47am projectredcap.org

1. Income level in INR per month Below 10,000 10,001-20,000

20,001-30,000

30,001-50,000

50,001-80,000

80,001-1,00,000

Above 1,00,000 Not known

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. Mechanism of injury

(Coded using ICD 10. Source: Medical record)

1. Clinical Frailty Scale 1. Very fit
2. Fit
3. Managing well
4. Living with very mild frailty
5. Living with mild frailty
6. Living with moderate frailty
7. Living with severe frailty
8. Living with very severe frailty
9. Terminally ill Not known

(Source: Medical record or treating physician)

1. Comorbidities (Charlson Comorbidity Index)  Myocardial infarction

 Congestive heart failure

 Peripheral vascular disease  Cerebrovascular disease

 Dementia

 Chronic pulmonary disease  Rheumatologic disease

 Peptic ulcer disease  Liver disease

 Diabetes

 Hemiplegia or paraplegia  Renal disease

 Malignancy  Leukemia  Lymphoma  AIDS

 Not known  None

(Source: Medical record, treating physician or interview)

1. Severity of liver disease Mild

Moderate or severe Not known

(Source: Medical record, treating physician or interview)

1. Severity of diabetes Controlled

Uncontrolled Not known

(Source: Medical record, treating physician or interview)

15-11-2024 10:47am projectredcap.org

*Page 8*

1. Severity of malignancy Localized

Metastatic tumor Not known

(Source: Medical record, treating physician or interview)

15-11-2024 10:47am projectredcap.org

**Prehospital V1.0.01.10.24**

*ATLS*

*Page 9*

1. Date and time of injury

(Source: Medical record of interview)

1. Mode of transport to the participating hospital Ambulance Police

Private vehicle Walking Others

Not known

(Source: Medical record of interview)

1. If other, please specify

(Source: Medical record of interview)

1. Referred or transferred to the participating Yes

hospital from another hospital No

Not known

(Source: Medical record of interview)

15-11-2024 10:47am projectredcap.org

**ATLS adherence V1.1.22.10.24**

*ATLS*

*Page 10*

ATLS adherence checklist

**Airway**

1. Airway patency checked Yes

No

(Source: Observation)

**Breathing**

1. Chest wall palpated Yes

No

(Source: Observation)

1. Breath sounds checked Yes

No

(Source: Observation)

1. Respiratory rate measured Yes

No

(Source: Observation)

1. Saturation (SpO2) measured Yes

No

(Source: Observation)

**Circulation**

1. Heart rate measured Yes

No

(Source: Observation)

1. Blood pressure measured Yes

No

(Source: Observation)

1. Abdomen palpated Yes

No

(Source: Observation)

1. Thighs palpated Yes

No

(Source: Observation)

1. IV access obtained Yes

No

(Source: Observation)

15-11-2024 10:47am projectredcap.org

**Disability**

1. GCS checked Yes

No

(Source: Observation)

1. Pupils checked Yes

No

(Source: Observation)

**Exposure**

1. Patients exposed for assessment Yes No
2. Temperature measured Yes

No

(Source: Observation)

1. Interventions and adjuncts performed according to ATLS

**Airway interventions**

1. Which airway interventions were performed?  None

 Manual airway procedure such as chin lift or jaw thrust

 Nasopharyngeal or Oropharyngeal airway inserted  Supraglottic airway device

 Tracheal intubation  Surgical airway

 Other

 Not known (Source: Observation)

1. If other airway Interventions given, specify
2. Were airway interventions performed while Yes

minimising c-spine movement? No

Not known (Source: Observation)

**Breathing interventions**

1. Which breathing interventions were performed?  None

 Oxygen applied

 Intracostal drain placement  Other

 Not done  Not known

(Source: Observation)

1. If other breathing Interventions done, specify

15-11-2024 10:47am projectredcap.org

*Page 12*

**Circulation interventions**

1. Which circulation interventions and adjuncts were  None

performed?  Control of external bleeding

 Fluid bolus

 Blood transfusion  eFast

 Pelvic binder applied

 Reduction of highly displaced fracture  Other

 Not known (Source: Observation)

1. If other circulation Interventions done, specify

**Disability interventions**

1. Which disability intervention was performed?  None

 Placement of definitive airway if the patient had a GCS of 8 or less

 Log Rolling

 Spine board during transportation  Other

 Not known (Source: Observation)

1. If other disability interventions done, specify

**Exposure interventions**

1. Which exposure intervention was performed?  None

 Covered with warmer or blanket  Warm fluids administered

 Other

 Not known (Source: Observation)

1. If other exposure interventions done, specify

15-11-2024 10:47am projectredcap.org

**Emergency Department V1.0.01.10.24**

*ATLS*

*Page 13*

1. Date and time of arrival to the emergency department at the participating hospital

(Source: Medical record of interview)

1. First recorded systolic blood pressure (mmHg)

(Source: Medical record)

1. First recorded diastolic blood pressure (mmHg)

(Source: Medical record)

1. First recorded heart rate (beats per minute)

(Source: Medical record)

1. First recorded respiratory rate (breaths per minute)

(Source: Medical record)

1. First recorded Glasgow Coma Scale

(Source: Medical record)

1. First recorded body temperature (°C)

(Source: Medical record)

1. First recorded oxygen saturation (%)

(Source: Medical record)

1. Emergency department disposition Admitted

Referred or transferred for admission Dead

Others Not known

(Source: Medical record)

1. If other, please specify

(Source: Medical record)

1. Date and time of referral or transfer for admission

(Source: Medical record)

15-11-2024 10:47am projectredcap.org

**Hospital V1.0.01.10.24**

*ATLS*

*Page 14*

1. Date of admission to the participating hospital

(Source: Medical record)

* 1. Time of admission to the participating hospital

(Source: Medical record)

1. Type of admitting ward General surgery

Orthopaedics Neurosurgery Intensive care unit High dependency unit Medicine

Trauma ward Not known

(Source: Medical record)

1. Ward name or number

(Source: Medical record)

1. Admitted to intensive care unit during admission Yes No

Not known

(Source: Medical record)

1. Date of first intensive care unit admission

(Source: Medical record)

* 1. Time of first intensive care unit admission

(Source: Medical record)

1. Date of first intensive care unit discharge

(Source: Medical record)

* 1. Time of first intensive care unit discharge

(Source: Medical record)

1. Hospital disposition Alive

Dead

Transferred for admission Not known

(Source: Medical record)

1. Was the patient transferred to another hospital for Yes

admission? No

Not known

(Source: Medical record)

15-11-2024 10:47am projectredcap.org

*Page 15*

1. Date of discharge or transfer from participating hospital

(Source: Medical record)

* 1. Time of discharge or transfer from participating hospital

(Source: Medical record)

15-11-2024 10:47am projectredcap.org

**Surgery V1.0.01.10.24**

*ATLS*

*Page 16*

1. Date of surgical procedure

(A surgical procedure is defined as any procedure performed in the operating room, interventional dropdownlogy suite, or at the bedside, requiring general or regional anesthesia. Source: Medical record)

1. Time of surgical procedure

(A surgical procedure is defined as any procedure performed in the operating room, interventional dropdownlogy suite, or at the bedside, requiring general or regional anesthesia. Source: Medical record)

1. Preoperative ASA score 1. A normal healthy patient

2. A patient with mild systemic disease

1. A patient with severe systemic disease
2. A patient with severe systemic disease that is a constant threat to life
3. A moribund patient who is not expected to survive without the operation
4. A declared brain-dead patient whose organs are being removed for donor purposes

 999. Not known

(Source: Medical record or treating physician)

1. Description of procedure

(Source: Medical record)

1. Procedure coded according to SNOMED CT

(Source: Medical record)

15-11-2024 10:47am projectredcap.org

**Imaging V1.0.01.10.24**

*ATLS*

*Page 17*

1. Date and time of imaging

(Source: Medical record)

* 1. Time of imaging

(Source: Medical record)

1. Type of imaging Ultrasound

X-ray

Computed Tomography (CT) Magnetic Resonance Imaging (MRI)

(Source: Medical record)

15-11-2024 10:47am projectredcap.org

**Transfusion V1.0.01.10.24**

*ATLS*

*Page 18*

1. Date of transfusion

(Source: Medical record)

* 1. Time of transfusion

(Source: Medical record)

1. Type of blood product Packed red blood cells Platelets

Fresh frozen plasma Whole blood

Other

(Source: Medical record)

* 1. Other specify

1. Number of units transfused

(Source: Medical record)

15-11-2024 10:47am projectredcap.org

**Injury V1.0.01.10.24**

*ATLS*

*Page 19*

1. Injury description

(Source: Medical record)

1. ICD 10 code

(Coded using ICD 10. Source: Medical record)

1. Injury source data Medical record

X-ray report CT-report Surgical notes

(Source: Medical record)

1. Injury time

15-11-2024 10:47am projectredcap.org

**Individual Mortality Status V1.0.01.10.24**

*ATLS*

*Page 20*

1. Is the patient dead? Yes

No

(Source: Medical record or interview)

1. Date and time of death

(Source: Medical record or interview)

15-11-2024 10:47am projectredcap.org

*Page 21*

Health Questionnaire English version

VERSION FOR INTERVIEWER ADMINISTRATION

© EuroQol Research Foundation. EQ-5D™ is a trade mark of the EuroQol Research Foundation. UK (English) v1.2

Note to interviewer: although allowance should be made for the interviewer's particular style of speaking, the wording of the questionnaire instructions should be followed as closely as possible. In the case of the EQ-5D-5L descriptive system of the questionnaire, the precise wording must be followed.

If the respondent has difficulty choosing a response or asks for clarification, the interviewer should repeat the question word for word and ask the respondent to answer in a way that most closely resembles his or her thoughts about his or her health today.

© EuroQol Research Foundation. EQ-5D™ is a trade mark of the EuroQol Research Foundation. UK (English) v1.2

INTRODUCTION

(Note to interviewer: please read the following to the respondent.)

We are trying to find out what you think about your health. I will explain what to do as I go along, but please interrupt me if you do not understand something or if things are not clear to you. There are no right or wrong answers. We are interested only in your personal view.

First, I am going to read out some questions. Each question has a choice of five answers. Please tell me which answer best describes your health TODAY.

Do not choose more than one answer in each group of questions.

(Note to interviewer: first read all five options for each question. Then ask the respondent to choose which one applies to him/herself. Repeat the question and options if necessary. Mark the appropriate box under each heading. You may need to remind the respondent regularly that the timeframe is TODAY.)

© EuroQol Research Foundation. EQ-5D™ is a trade mark of the EuroQol Research Foundation. UK (English) v1.2

EQ-5D DESCRIPTIVE SYSTEM

© EuroQol Research Foundation. EQ-5D™ is a trade mark of the EuroQol Research Foundation. UK (English) v1.2

Date of filling this form

15-11-2024 10:47am projectredcap.org

First, I would like to ask you about MOBILITY. Would you say that: (Requires opt-in consent, not routinely recorded. Source: Interview)

You have no problems in walking about? You have slight problems in walking about?

You have moderate problems in walking about? You have severe problems in walking about?

You are unable to walk about?

© EuroQol Research Foundation. EQ-5D™ is a trade mark of the EuroQol Research Foundation. UK (English) v1.2

Next, I would like to ask you about SELF-CARE. Would you say that: (Requires opt-in consent, not routinely recorded. Source: Interview)

You have no problems washing or dressing yourself? You have slight problems washing or dressing yourself?

You have moderate problems washing or dressing yourself? You have severe problems washing or dressing yourself?

You are unable to wash or dress yourself?

© EuroQol Research Foundation. EQ-5D™ is a trade mark of the EuroQol Research Foundation. UK (English) v1.2

Next, I would like to ask you about USUAL ACTIVITIES, for example, work, study, housework, family or leisure activities. Would you say that:

(Requires opt-in consent, not routinely recorded. Source: Interview)

You have no problems doing your usual activities? You have slight problems doing your usual activities?

You have moderate problems doing your usual activities? You have severe problems doing your usual activities?

You are unable to do your usual activities?

© EuroQol Research Foundation. EQ-5D™ is a trade mark of the EuroQol Research Foundation. UK (English) v1.2

Next, I would like to ask you about PAIN OR DISCOMFORT. Would you say that: (Requires opt-in consent, not routinely recorded. Source: Interview)

You have no pain or discomfort? You have slight pain or discomfort?

You have moderate pain or discomfort? You have severe pain or discomfort?

You have extreme pain or discomfort?

© EuroQol Research Foundation. EQ-5D™ is a trade mark of the EuroQol Research Foundation. UK (English) v1.2

Finally, I would like to ask you about ANXIETY OR DEPRESSION. Would you say that: (Requires opt-in consent, not routinely recorded. Source: Interview)

You are not anxious or depressed? You are slightly anxious or depressed?

You are moderately anxious or depressed? You are severely anxious or depressed?

You are extremely anxious or depressed?

© EuroQol Research Foundation. EQ-5D™ is a trade mark of the EuroQol Research Foundation. UK (English) v1.2

EQ-5D VAS

© EuroQol Research Foundation. EQ-5D™ is a trade mark of the EuroQol Research Foundation. UK (English) v1.2

15-11-2024 10:47am projectredcap.org

*Page 23*

Now, I would like to ask you to say how good or bad your health is TODAY.

I would like you to picture in your mind a vertical line that is numbered from 0 to 100. (Note to interviewer: if interviewing face-to-face, please show the respondent the VAS line.)

100 at the top of the line means the best health you can imagine. 0 at the bottom of the line means the worst health you can imagine.

© EuroQol Research Foundation. EQ-5D™ is a trade mark of the EuroQol Research Foundation. UK (English) v1.2

I would now like you to tell me the point on this

|  |  |  |  |
| --- | --- | --- | --- |
| line where you would put your health TODAY. | 0 - The worst |  | 100 - The best |
| (Note to interviewer: mark the line at the point | health you can |  | health you can |
| indicating the respondent's health today.) | imagine | 50 | imagine |

*(Place a mark on the scale above)*

© EuroQol Research Foundation. EQ-5D™ is a trade mark of the EuroQol Research Foundation. UK (English) v1.2

15-11-2024 10:47am projectredcap.org

**Disability (WHODAS 2.0)**

*ATLS*

*Page 24*

Date of form filling

1. Who are you interviewing? Patient participant Patient representative

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. What is the relationship between the representative Husband or wife and the participant? Parent

Son or daughter Brother or sister Other relative Friend Professional carer Other (specify)

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. If other, please specify

**Instructions to the interviewer are written in bold - do not read these aloud.**

**Text for the respondent to hear is written in italic print in blue. Read this text aloud. Say to respondent:**

**The interview is about difficulties people have because of health conditions.**

**By health condition I mean diseases or illnesses, or other health problems that may be short or long lasting; injuries; mental or emotional problems; and problems with alcohol or drugs.**

**Remember to keep all of your health problems in mind as you answer the questions. When I ask you about difficulties in doing an activity think about...**

**Increased effort Discomfort or pain Slowness Changes in the way you do the activity When answering, I'd like you to think back over the past 30 days. I would also like you to answer these questions thinking about how much difficulty you have had, on average, over the past 30 days, while doing the activity as you usually do it.**

**Use this scale when responding: None, mild, moderate, severe, extreme or cannot do.**

**In the past 30 days, how much difficulty did you have in:**

15-11-2024 10:47am projectredcap.org

1. Standing for long periods such as 30 minutes? None Mild Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. Taking care of your household responsibilities? None Mild Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. Learning a new task, for example, learning how to None

get to a new place? Mild

Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. How much of a problem did you have joining in None

community activities (for example, festivities, Mild

religious or other activities) in the same way as Moderate

anyone else can? Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. How much have you been emotionally affected by your None health problems? Mild

Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

**In the past 30 days, how much difficulty did you have in:**

1. Concentrating on doing something for ten minutes? None

Mild Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. Walking a long distance such as a kilometre [or None

equivalent]? Mild

Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

15-11-2024 10:47am projectredcap.org

*Page 26*

1. Washing your whole body? None

Mild Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. Getting dressed? None

Mild Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. Dealing with people you do not know? None Mild Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. Maintaining a friendship? None

Mild Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. Your day-to-day work/school? None Mild Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)



15-11-2024 10:47am

projectredcap.org

**Instructions to the interviewer are written in bold - do not read these aloud.**

**Text for the respondent to hear is written in italic print in blue. Read this text aloud. Say to respondent:**

**The interview is about difficulties people have because of health conditions.**

**By health condition I mean diseases or illnesses, or other health problems that may be short or long lasting; injuries; mental or emotional problems; and problems with alcohol or drugs.**

**Remember to keep all of your health problems in mind as you answer the questions. When I ask you about difficulties in doing an activity think about...**

**Increased effort Discomfort or pain Slowness Changes in the way you do the activity When answering, I'd like you to think back over the past 30 days and, to the best of your knowledge, answer these questions thinking about how much difficulty your friend, relative or carer had while doing the following activities. I will use the term "relative" to mean "friend", "relative"**

**or "carer". For each question, please give only one response.**

**In the past 30 days, how much difficulty did your relative have in:**

1. Standing for long periods such as 30 minutes? None Mild Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. Taking care of his or her household None

responsibilities? Mild

Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. Learning a new task, for example, learning how to None

get to a new place? Mild

Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. How much of a problem did he or she have joining in None community activities (for example, festivities, Mild

religious or other activities) in the same way as Moderate

anyone else can? Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. How much has your relative been emotionally None

affected by his or her health condition? Mild Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

**In the past 30 days, how much difficulty did your relative have in:**

1. Concentrating on doing something for ten minutes? None

Mild Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. Walking a long distance such as a kilometre [or None

equivalent]? Mild

Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

*Page 28*

1. Washing his or her whole body? None Mild Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. Getting dressed? None

Mild Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. Dealing with people he or she does not know? None Mild Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. Maintaining a friendship? None

Mild Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. His or her day-to-day work/school? None Mild Moderate Severe

Extreme or cannot do

(Requires opt-in consent, not routinely recorded. Source: Interview)

**Number of days**

1. Overall, in the past 30 days, how many days were these difficulties present?

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. In the past 30 days, for how many days were you totally unable to carry out your usual activities or

work because of any health condition? (Requires opt-in consent, not routinely recorded.

Source: Interview)

1. In the past 30 days, not counting the days that you were totally unable, for how many days did you cut

back or reduce your usual activities or work because (Requires opt-in consent, not routinely recorded. of any health condition? Source: Interview)

15-11-2024 10:47am projectredcap.org

**Return To Work V1.0.01.10.24**

*ATLS*

*Page 29*

Date of form filling

1. Did participant returned to work? Yes No
2. Date and time of return to work

(Requires opt-in consent, not routinely recorded. Source: Interview)

1. Work status Paid work

Self-employed, such as own your business or farming Non-paid work, such as volunteer or charity

Student

Keeping house/homemaker Not known

(Requires opt-in consent, not routinely recorded. Source: Interview)

15-11-2024 10:47am projectredcap.org

**Safety Events V1.0.01.10.24**

*ATLS*

*Page 30*

1. Date reported to trial management team of safety event
2. Type of safety event Prolonged mechanical ventilation (> 7 days) Initiation of renal replacement therapy

Prolonged (> 2 days) use of vasopressors such as norepinephrine or vasopressin

 Renewed (restart after at least 2 days without) use of vasopressors such as norepinephrine or vasopressin

 Other

(Source: Medical record or treating physician)

1. Elaborate on other safety event

(Source: Medical record or treating physician)

1. Investigator assessment of safety event

(Source: Investigator)

15-11-2024 10:47am projectredcap.org

**End Of Study V1.0.01.10.24**

*ATLS*

*Page 31*

1. What is the reason for the end of study? Completed follow up Lost to follow up Death

Discharge and no consent for follow up

Opt-out from routinely recorded (in-hospital) data collection and no consent for follow-up

 Opt-out from routinely recorded (in-hospital) data collection and withdrawn consent for follow-up

1. Date and time of end of study

15-11-2024 10:47am projectredcap.org

**End Of Study V10 Dated22mar24**

*ATLS*

*Page 32*

What is the reason for the end of study? Completed follow up Lost to follow up Death

Discharge and no consent for follow up

Opt-out from routinely recorded (in-hospital) data collection and no consent for follow-up

 Opt-out from routinely recorded (in-hospital) data collection and withdrawn consent for follow-up

Date and time of end of study

26-08-2024 8:06pm projectredcap.org